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Abstract
The epidemic of metabolic diseases such as diabetes has become a public health concern.
Previous research data from our lab have shown that vitamin A (VA) status and retinoic acid
(RA), a metabolite of VA, contribute to the glucose and lipid metabolism in the body and cells.
As the skeletal muscle contributes to metabolic homeostasis, the effects of VA signaling system
on its glucose metabolism are worth to be investigated. Here in this dissertation, the following
two projects were carried out to study the VA’s role in the control of metabolism. (1) The
effects of VA status on the development of type 2 diabetes mellitus (T2DM) were studied in
Zucker diabetic fatty (ZDF) rats fed a VA deficient (VAD), VA marginal (VAM) or VA
sufficient (VAS) diet with basal fat (BF) or high fat (HF) content for 8 weeks. Zucker lean (ZL)
rats fed the same diets were used as controls. We found that VA statuses affect body mass gain
in ZL/ZDF rats in BF/HF diets. The mRNA and protein levels of lipogenic genes were reduced
when the dietary VA dropped in ZL/ZDF rats fed the BF diets. Interestingly, the effects of VA
status on lipogenesis in ZDF rats were masked in the presence of HF diets. Therefore,
controlling VA intake and its metabolism may help to prevent obesity and T2DM in ZDF rats.
(2) The effects of insulin and RA on the glucose transporter 4 (GLUT4) expression in L6 cells
were studied. To determine the specificity of commercially available antibodies, we
constructed a recombinant adenovirus overexpressing GLUT4 protein (Ad-mGLUT4), and
successfully used it to determine a functional and workable antibody for the detection of
GLUT4 in L6 cells. The rats L6 muscle cells were treated with or without 10 nM insulin in the
absence or presence of 1μM RA for 4 or 6 days and fractionated to prepare different lysates.
v

We found that RA alone and in combination with insulin induced the translocation of GLUT4
on the membrane of differentiated L6 muscle cells. RA + insulin induced the GLUT4
expression in total lysate of L6 cells on day 4.
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Chapter One
Introduction
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Parts of this chapter were originally published by Tiannan Wang, Jing Wang, Xinge Hu,
Xianju Huang, and Guoxun Chen:
Wang T, Wang J, Hu X, Huang XJ, Chen GX. Current understanding of glucose transporter 4
expression

and

functional

mechanisms.

World

J

Biol

Chem.

2020;11(3):76-98.

doi:10.4331/wjbc.v11.i3.76
Some parts of this chapter, which were from the published article have been briefly revised
in the following ways: section order changes, font changes, figure and table numbers change
to adapt to the format of this dissertation, and some detailed instructions have been added.
The content published in this article is contributed by Tiannan Wang. Guoxun Chen is the
corresponding author and contributed to the outline and writing of the manuscript.
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1. Vitamin A (VA)
1.1 The Discovery of VA
VA (retinol) is an essential micronutrient for normal growth, vision, reproduction,
immunity, cell differentiation and metabolism in humans (1). As a fat-soluble micronutrient,
VA activity was observed during the study of the role of dietary fats. In the 1880s, Nicolai
Lunin showed an unknown substance in milk that is essential for nutrition (2). He found that
mice cannot live on a diet of pure casein, fat, sucrose, minerals and water, but can live with
whole milk and grow normally (3). In 1912, Hopkins showed that "accessory factors" in milk
supported life for the normal growth of rats (2). After that VA was discovered by E. V.
McCollum in 1913 when he had found a fat-soluble factor that promoted growth in rats and
showed that this factor was essential for growth and survival (3). The "accessory factor" was
named “fat-soluble factor A” in 1918, later, factor A and then VA in 1920 (2). Also, Thomas
Osborne and Lafayette Mendel at exactly the same time performed similar experiments (3).
Paul Karrer isolated β-carotene (the main dietary provitamin A) and retinol (VA), and
described VA chemical structure in 1932 (4, 5). Harry Holmes and Ruth Corbet isolated and
crystallized VA in 1937 (6). Later, David Adrian van Dorp and Jozef Ferdinand Arens
developed a method for the synthesis of VA in 1946 (7), and Otto Isler and colleagues
completed the full chemical synthesis of VA in 1947 (8). VA is required for humans to develop
the normal functions of the nervous and visual systems (9). The visual cycle requires the
formation of retinal. In addition, VA can also affect cell differentiation and proliferation,
maintain epithelial cell integrity, immune function and reproduction (9).
3

1.2 Sources, Digestion, and Absorption of VA
VA cannot be synthesized by mammals themselves, so it needs to be obtained from dietary
sources. Dietary VA activity exists in two forms, preformed VA and provitamin A. Preformed
VA is classified as retinyl ester, retinol, retinal, retinoic acid (RA), and found in foods from
animal products such as meat, fish, liver, poultry, and dairy products (10). Liver and fish oil
have the highest concentration of preformed VA (11). Provitamin A, carotenoids, is mainly
found in plant sources, such as leafy green vegetables, orange and yellow vegetables, tomato
products, fruits, and some vegetable oils (11). Representative sources of provitamin A include
carrots, broccoli, cantaloupe, squash, peas, and spinach, etc (1). There are three different
isomers of carotenoids present in foods. The most important provitamin A carotenoid is βcarotene, which is present abundantly in carrots and yellow and green leafy vegetables (1).
Other provitamin A carotenoids are α-carotene and β-cryptoxanthin. Carrots and red palm oil
are the major contributor of α-carotene; and β-cryptoxanthin is mainly found in fruits (1).
Carotenoids must be converted to retinoid first. In the small intestinal cells, β-carotene is
enzymatically converted into two molecules of retinal.
Different forms of molecules with VA activity are absorbed from the diet. In the diet
derived from animal source, retinol is often esterified with fatty acids (FAs) to form retinyl
esters (RE). In the stomach, dietary REs and carotenoids are in complexes with proteins, which
are digested by pepsin (a protease). The REs and carotenoids are released after digestion and
coalesce to form fat globules. These fat globules are then moved into the duodenum where
proteolytic enzymes further hydrolyze proteins and release more REs or carotenoids. In the
4

lumen of the small intestine, REs cannot enter the intestinal mucosa and must first be digested
by the intraluminal retinol ester hydrolase (REH) to produce a free retinol and FAs (12). In the
water-soluble micelles formed by bile salts, the solubilized REs and triglycerides (TGs) are
hydrolyzed by various hydrolases into retinol and other products (1). REs can be hydrolyzed
into retinol and FAs by intestinal brush border or nonspecific pancreatic enzymes (such as
pancreatic TG lipase and cholesterol ester hydrolase) in the intestinal lumen, and then the
products are absorbed by the enterocytes. Dietary retinol is directly absorbed by mucosal cells
(13).
Contrary to preformed VA in the diet, carotenoids (such as β-carotene) in the diet can be
converted into retinal within the enterocyte or absorbed unmodified by these cells (12).
Carotenoids are also solubilized into micelles in the intestinal lumen from which they are
absorbed into duodenal mucosal cells by a passive diffusion mechanism (1). After being taken
up by enterocytes, retinol can bind to the retinol binding protein type II (CRBP-II). This protein
helps to dissolve retinol and prevent its degradation. Then, retinol associated with CRBPII is
reesterified with long-chain fatty acids mainly by the action of lecithin:retinol acyltransferase
(LRAT) to form RE.
The digested dietary lipids are reesterified into TGs and phospholipids, and then packed
with apolipoprotein B48 (Apo B48) and other dietary lipophilic factors in the enterocytes (14).
The newly formed REs are also packaged with triacylglycerols, phospholipids, and cholesterol
esters into nascent chylomicrons in the enterocytes and secreted into the lymphatic system
before entering into the general blood circulation (12). TGs are hydrolyzed by lipoprotein
5

lipase in the general circulation and formed as chylomicron remnants (15). REs and carotenoids
in chylomicron remnants are transported to the liver through plasma. After that, REs are
hydrolyzed, and then reesterified and stored in liver cells. Some REs can also be taken up
directly by peripheral tissues (1). The liver is the major organ for VA storage. Some REs are
stored in the liver parenchymal cells, but almost 80%-95% of REs are stored in the stellate cells
(16).
REs are stored together with lipid droplets in stellate cells until it is necessary to maintain
a normal blood retinol concentration. To meet tissue needs for VA, the released retinol from
the liver binds with retinol binding protein 4 (RBP4), which is released with VA into the
circulation then transported to various tissues (including the eye) of the body through the blood
for normal metabolism (17). RBP4 is mainly synthesized in hepatocytes and is a specific
transporter protein of retinol in the blood. Almost all circulating retinol binds to RBP4, while
CRBPs and cellular RA Binding proteins (CRABPs) carry retinoids in cells (18, 19).
1.3 Metabolism of VA
Retinol is metabolized in the liver to a variety of products, and some of which are
combined with glucuronic acid or taurine to be excreted in the bile (1). When the liver VA
exceeds the critical concentration, the amount of VA metabolite excreted in the bile increases.
This increased excretion is believed to be a protective mechanism that reduces the risk of
excessive storage of VA. Other VA metabolites are excreted in the urine (1).
Retinol derived from REs and provitamin A carotenoids is oxidized to retinal and then to
RA. Retinol can be released from RE stores through the action of REH, and retinol can be
6

reesterified at its hydroxyl group again to produce REs by LRAT. Retinol can be oxidized to
retinal by retinol dehydrogenase. Provitamin A, β-carotene is cleaved by β-carotene-15,15‘oxygenase 1 (BCO1) to retinaldehyde. Retinaldehyde can be reduced to retinol by retinol
dehydrogenases (RDHs) or oxidized into RA by retinaldehyde dehydrogenase (RALDH). RA
possess a carboxylic acid group (-COOH). After RA synthesis, it is translocated to the nucleus,
where it regulates gene expressions through activations of transcription factors such as RA
receptors (RARs) and retinoid X receptors (RXRs). RA induces the expression of
cytochrome P450 enzymes (CYP26A1), which modifies RA and contributes to RA
homeostasis. CYP26A1 controls RA catabolism to maintain RA levels in vivo (12).
1.4 VA’s Role in Metabolism
As an essential and lipophilic micronutrient, VA is implicated in the regulation of glucose
and lipid metabolism (17). VA status has played a role in regulating the expression of critical
genes in different metabolic pathways, such as in glucose, FA and TG metabolism. In 1937,
liver samples from patients who died of diabetes showed elevated levels of VA (17). The direct
effects of RA on the expression of glucokinase gene (Gck) in primary rat hepatocytes have
been studied (20). Glucokinase serves as an insulin-dependent modulator of glucose utilization
in the liver and functions as a glucose sensor in pancreatic β-cells (21). We showed that retinoid
and insulin can synergistically induce the expression of Gck and Sterol regulatory elementbinding protein 1 (Srebp-1c) in primary rat hepatocytes. Srebp-1c is a critical transcription
activator for hepatic cholesterol and fatty acid biosynthesis, and their homeostasis (22). On the
other hand, retinoids attenuate insulin-inhibited the cytosolic form of phosphoenolpyruvate
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carboxykinase 1 (Pck1) expression in the same cells, which is the rate limiting enzyme of
hepatic gluconeogenesis and impacts lipid metabolism (17).
Hepatic VA content seems to be directly related to the hepatic glycogen content as reduced
hepatic glycogen content in the liver of vitamin A deficient (VAD) rats has been observed in
our laboratory (17). When rats were fed foods containing excessive VA, an increase in liver
glycogen content was observed. In addition, we have found that VA status can affect the
development of obesity in Zucker fatty (ZF) rats and control plasma TG levels in ZL and ZF
rats (17). The plasma glucose, TG, insulin and leptin levels of VAD ZL and ZF rats were lower
than those of corresponding vitamin A sufficient (VAS) rats. The liver glycogen content of
VAD rats, the net weight of epididymal fat and liver, and the ratio of fat to body weigthBM
(ZL only) were also lower than those of VAS rats (17).
1.5 VA Assessment, Deficiency and Toxicity
Before the clinical signs and symptoms of VA deficiency or toxicity appear, there are
methodological difficulties in assessing the VA status in the population. The xerophthalmia
classification is traditionally used to identify people with VA deficiency (23). Currently, the
dietary intake of VA, night blindness, and dark adaptation have been used as assessment
methods in population evaluation (23). Plasma retinol concentrations and blood RBP4 levels
are also used to determine the risk of VA deficiency. However, in healthy individuals, the
plasma retinol concentration is under homeostatic control and will not start to decline until the
liver's VA reserve drops to a very low level (23). Although it is difficult to obtain liver samples,
liver RE content is considered the best indicator of VA status because the majority of VA is
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stored in the liver. Because all these methods have limitations, the most reliable nutritional
assessment of VA status may be a combination of them.
The uptake of the right amount of VA is very important to human health. The Dietary
Reference Intakes established by the Food and Nutrition Board at the Institute of Medicine
(IOM) of the National Academies provides recommendations for the intake of VA and other
nutrients (1). For many years, the International Unit (IU) has been used to define VA activity.
However, in 2001, the American IOM recommended the use of the new unit. According to age
and gender, the Recommended Dietary Allowance (RDA) of VA is given in micrograms (μg)
of retinol activity equivalent (RAE) to illustrate the different biological activities of retinol and
provitamin A carotenoids. These are all converted by the body into retinol. One microgram of
RAE is equivalent to 1 microgram of retinol, 2 micrograms of supplementary β-carotene, 12
micrograms of dietary β-carotene or 24 micrograms of dietary α-carotene or β-cryptoxanthin
(1). According to data from IOM, the RDA for VA is 900 μg RAE for men, 700 μg RAE for
women, and 770 μg RAE for pregnant women at age between 19 to 50 years old (1).
VA's involvement in cell morphogenesis, differentiation and proliferation is essential for
gene regulation. In addition, its function as an antioxidant can reduce the damage of DNA by
free radicals (24). Both VA deficiency and VA toxicity due to excess VA can negatively affect
many physiological processes in the body. Adequate VA is defined as plasma retinol levels>
1.05 umol/L. A retinol level <0.7 umol/L is defined as VA deficiency. VA deficiency is rare in
the United States, but is common in many developing countries. This is usually because
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residents cannot obtain food containing preformed VA from animal food sources, and due to
poverty, they usually do not consume available food containing β-carotene (11).
VA deficiency is thought to cause xerophthalmia. One of the early signs of xerophthalmia
is night blindness, which is the inability to see in low light or darkness. In addition, the growth
of children may be affected due to a lack of VA (25). Excessive amounts of VA may cause
various adverse effects. A single intake of 25,000 IU/kg or more of VA may cause acute
toxicity. Signs and symptoms include nausea, vomiting, diarrhea, dizziness, drowsiness,
drowsiness, increased intracranial pressure, and skin changes such as erythema, itching, or
scaling (10). Excessive intake of 4,000 IU/kg or more of VA per day may cause chronic toxicity
for 6-15 months. Signs and symptoms include low-grade fever, headache, fatigue, anorexia,
intestinal disorders, hepatosplenomegaly, anemia, hypercalcemia, subcutaneous swelling,
nocturia, joint and bone pain, and skin changes such as yellowing, dryness, hair loss and
photosensitivity (10). If excessive amount of VA is taken during pregnancy, it is highly
teratogenic (26).
2. Skeletal Muscle
2.1 Skeletal Muscle Development
The term "muscle" covers a variety of cell types. Mammals have four main types of
muscle cells: skeletal, heart, smooth, and myoepithelial cells. They are different in function,
structure and development (27). The skeletal muscle mass accounts for 40% of the total body
mass, and the regulation of skeletal muscle glucose metabolism will significantly affect the
body's glucose homeostasis (28-30). Skeletal muscle is composed of many muscle fibers
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connected by collagen and reticular fibers. Each skeletal muscle fiber is a syncytium that
derives from the fusion of many myoblasts. Myoblasts proliferate in large quantities, but once
fused, they no longer divide. The fusion usually follows the onset of myoblast differentiation
(27). Different fiber types have distinct contractile and metabolic properties (31). The skeletal
muscle maintains skeletal structure and essential daily activities (32). Also, it is a source of
proteins that can be broken down into amino acids for the body to use.
Skeletal muscle is the main target of insulin-stimulated glucose uptake. Skeletal muscle
can store glucose in the form of glycogen and use it for energy production in physical activity
(33). Obesity and T2DM have a negative effect on skeletal muscle glucose metabolism.
Therefore, skeletal muscle can not only maintain the physical performance of the body, but
also protect against various metabolic diseases such as insulin resistance (32), it is important
to understand the relationship between muscle glucose metabolism and metabolic diseases.
2.2 L6 Rat Skeletal Muscle Cells (L6 cells)
L6 rat skeletal muscle cells (L6 cells) were isolated from the thigh tissue of a newborn rat
(34). L6 cells can still maintain their myoblast morphology, have a high differentiation rate,
and can differentiate and fuse to form multinucleated fibers (35). They have been used to study
the proliferation and differentiation of myoblasts. L6 myotubes have been used to study the
insulin-stimulated glucose transport. They uptake glucose in response to insulin stimulation,
an important biological response for glucose usage (28). In response to insulin, these cells have
shown greater glucose uptake and glucose transporter 4 (GLUT4) translocation than other in
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vitro murine skeletal muscle model systems (28). Therefore, L6 cells are an effective model
for studying skeletal muscle glucose metabolism.
3. Diabetes
Currently, diabetes is a problem of public health (36). Based on the American Diabetes
Association’s definition, diabetes is a serious chronic health condition of your body that causes
blood glucose levels to rise higher than normal, which will lead to multiple complications if
hyperglycemia is left untreated or mismanaged (37). Diabetes occurs when your body cannot
make insulin or cannot effectively respond to insulin to regulate blood glucose level. A fasting
blood glucose level of 99 mg/dL or lower is normal, 100 to 125 mg/dL means prediabetes, and
126 mg/dL or higher indicates diabetes (38). There are two type of diabetes, insulin-dependent
type 1 diabetes mellitus (T1DM) and -independent T2DM. T2DM accounts for about 90% to
95% of all diagnosed cases of diabetes, and is due to the lack of responses to insulin in the body
(39).
Insulin resistance is a characteristic of T2DM. For a person with diabetes, a major
challenge is to control or manage blood glucose level. Diabetes can lead to complications, such
as stroke, blindness, heart attack, kidney failure and amputation. Take the United States as an
example, more than 30 million people in the United States have diabetes (38). It is believed
that through diet and lifestyle interventions, T2DM can be reversed due to the correction of
overweight and obesity. Although more and more people are beginning to pay attention to how
to control the prevalence of diabetes, the roles of micronutrients in diabetes have not been fully
revealed.
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3.1 VA and Diabetes
Recently, research data have shown that VA as a micronutrient participates in the
regulation of glucose and lipid metabolism (40). Since diabetes is a metabolic disease, it is
imperative to reveal the relationship of VA and diabetes.
Common changes in VA metabolism in T1DM are the decrease in plasma VA levels in
human and animal studies, and the increase in the liver VA storage in animal studies. Studies
in Europe and the United States seem to indicate that T1DM reduces blood retinol levels in the
studied population, while studies in Japan are uncertain. In the French population, blood VA
levels in T1DM patients were lower compared to that in the control group (41). A Canadian
study shows that adolescent and young adults with T1DM have lower blood VA and RBP
levels than the control subjects (42). In the Italian population, the plasma retinol levels of young
TIDM diabetic patients were lower than those of the control group (43). In Spain, adults (male
and female) with T1DM have a lower VA status (44). In addition, a study of multi-case families
in the United States showed that serum retinol and RBP levels in patients with T1DM were
lower than those in non-diabetic patients (45). In the studies of streptozotocin (STZ)-induced
diabetic rats, the elevation of hepatic VA store at 3 weeks after the onset of diabetes seems to
show strain differences among Wistar Furth, Sprague Dawley and Wistar (46). This indicates
that the reduction of plasma retinol level depends on rat strains, which matches the human
studies.
The dietary VA intake and plasma VA levels of T2DM patients vary depending on the
population studied. Whether different dietary behaviors, regional food choices, genetic
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backgrounds, and disease stages play a role remains to be studied. Also, there has been a lack
of research investigating plasma VA levels in T2DM animals. RA is the active metabolite of
VA and has been extensively studied for the treatment of diabetes complications (11, 40).
Current data seem to indicate that the development of diabetes is related to changes in VA
metabolism.
3.2 Zucker Diabetic Fatty (ZDF) Rats for Diabetes Studies
ZF rats have a mutated leptin receptor leading to hyperphagia and development of obesity
(47). They have glucose intolerance, although do not develop diabetes. ZDF rats are a substrain
of the ZF rats, and develop hyperglycemia, which is a model for diabetes studies (48). ZDF
rats are characterized by developing diabetes at age between 7 to 12 weeks.
In 1977, the first ZDF rat was observed in a colony of Zucker rats and developed into a
production colony in the late 1980s (49). The genome of ZDF rats has a missense mutation in
the gene encoding the leptin receptor (fa/fa) (50), and ZDF rats spontaneously develop into
insulin resistance, T2DM, hyperlipidemia, moderate hypertension, obesity, and progressive
renal injury (51). ZDF male rats are more widely used as models of T2DM and diabetic
nephropathy. ZDF female rats show insulin resistance and obesity comparable to male rats.
However, hyperglycemia occurs only when they receive a diabetes diet (52). ZDF rats have
become the primary rat model for studying T2DM.
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4. Glucose Transport
4.1 Glucose Transporters (GLUTs)
Glucose is a common molecule used for production of energy or other metabolites in cells. As
a quick energy source, glucose can be metabolized aerobically or anaerobically depending on
the availability of oxygen or cell characteristics (53). Glucose is a hydrophilic molecule and
cannot diffuse into or out of a cell freely. It needs transporters to cross the cell membrane.
GLUTs are proteins that serve this purpose. The concept of GLUTs appeared in 1948 when it
was found that glucose could not pass through the cell membrane freely (54).
GLUTs are members of the major facilitator superfamily (MFS) transporters, which are
responsible for the transport of a large array of small molecules such as nutrients, metabolites
and toxins across the cell membrane (55). Multiple members have been identified in each
family of MFS transporters, and changes of their functions have been associated with several
diseases (55). Members of MFS transporters have 12 transmembrane helices, and transport
their substrates as uniporters, symporters or antiporters (55). Upon binding of the substrates on
one side of the membrane, a conformation change occurs, which is achieved through
coordinative interactions of those helices through a ‘clamp-and-switch’ mechanism. Structural
studies have shown that the substrate specificity is achieved through the conserved amino acid
residues within each family (55). Thus, it is important to understand GLUT functions,
expressions and regulations for the control of blood glucose homeostasis. The first transporter
identified is GLUT1, which is expressed universally in all cells, and responsible for basal
glucose transport (56).
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Since the identification and cloning of GLUT1, 13 additional GLUTs have been cloned
using recombinant DNA techniques (57). Table 1-1 summarizes names, numbers of amino
acids, Kms, expression profiles and potential functions of those GLUTs. Based on their
phylogeny or genetic and structural similarities, GLUTs are classified into three classes. Class
I includes GLUTs 1-4, and GLUT14 which are responsible for glucose transfer. Class II
consists of GLTUs 5, 7, 9 and GLUT 11 which are considered as fructose transporters. Class
III contains GLTUs 6, 8, 10, 12 and GLUT 13 (58). All the GLUTs have a lot of structural
similarity. All GLUTs have nearly 500 amino acid residues arranged in a 12 membrane
spanning helices (57).
GLUTs play a key role in transporting glucose across the plasma membranes in animals
and regulating glucose sensing and metabolic homeostasis. Each GLUT has its own unique
affinity and specificity for its substrate, tissue distribution, intracellular location, regulatory
mechanisms and physiological functions (59). The most well studied and known members are
GLUTs 1-6. The first transporter identified is GLUT1, which is expressed universally in all
cells, and responsible for basal glucose transport (56). GLUT1 is found evenly distributed in
the fetal tissues. In human adults, GLUT1 level is high in erythrocytes and endothelial cells. It
is responsible for basal glucose uptake (60). GLUT2 is expressed in the liver and pancreas, and
contributes to glucose sensing and homeostasis (59). In enterocytes, GLUT2 is responsible to
transport the absorbed glucose, fructose and galactose out of the basolateral membrane to enter
into the blood circulation through the portal vein (61). GLUT3 just like GLUT1 is expressed
in almost all mammalian cells and is responsible for the basal uptake of glucose. GLUT3 is
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considered as the main GLUT isoform expressed in neurons and the placenta, but has also been
detected in the testis, placenta, and skeletal muscle (62-64). GLUT5 is specific for the uptake
of fructose in a passive diffusion manner, and is expressed in the small intestine, testes and
kidney (59). GLUT6 is expressed in the spleen, brain, and leukocytes as well as in muscle and
adipose tissue (57, 65). GLUT6 has been shown to move from the intracellular locations and
plasma membrane of rat adipocytes in a dynamin-dependent manner (65).
4.2 Insulin and GLUTs
Dietary starch is first digested into glucose before being absorbed into the body and
utilized (53). Insulin stimulates glucose utilization in the body. This is in part through the
insulin-induced glucose uptake in the muscle and adipose tissues (66). In addition to insulin
stimulation, physical activity can also increase glucose entering into the skeletal muscle cells
(67).
The observation that insulin promotes the redistribution of GLUTs from intracellular
locations to the plasma membrane in adipocytes began in the 1980s (68-70). Few years later,
the insulin-induced glucose transport was also found in muscle cells (71, 72). To understand
the underlying mechanism of insulin-stimulated glucose uptake, antibodies against membrane
glucose transport proteins were created (73). Subcellular fractionation, cytokinin B (glucosesensitive ligand), and glucose absorption into isolated vesicles were used to study the
phenomenon. It was proposed that these GLUTs are moved from intracellular components to
the plasma membrane of adipocytes and muscle cells upon insulin stimulation (56). In 1988, a
specific antibody against a GLUT sample preparation was created, which eventually led to the
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Table 1-1: Summary of Glucose Transporter Family Members
Protein

Amino

Km

(gene)

acids

(mM)

GLUT1

492

3~7

(SLC2A1)
GLUT2

524

17

(SLC2A2)
GLUT3

496

1.4

Expression sites

Function/substrates

References

Ubiquitous distribution in

Basal glucose uptake; glucose, galactose,

(74-80)

tissues and culture cells

glucosamine, mannose

Liver, pancreas, brain,

High-capacity low-affinity transport; glucose,

(75-77, 79-

kidney, small intestine

galactose, fructose, glucosamine, mannose

84)

Brain and nerves cells

Neuronal transport; glucose, galactose,

(75-77, 79,

mannose

80, 83-85)

Muscle, fat, heart,

Insulin-regulated transport in muscle and fat;

(75-77, 79-

hippocampal neurons

glucose, glucosamine

81, 86, 87)

Intestine, kidney, testis,

Fructose

(75-77, 79,

(SLC2A3)
GLUT4

509

5

(SLC2A4)
GLUT5

501

6

(SLC2A5)

brain

80, 84, 8892)

GLUT6

507

5

Spleen, leukocytes, brain

Glucose

(SLC2A6)
GLUT7

80, 93)
524

0.3

(SLC2A7)
GLUT8

(75-77, 79,

Small intestine, colon,

Fructose and glucose

testis, liver
477

2

(SLC2A8)
GLUT9

Major

(SLC2A9)

540,

0.9

(75-77, 79,
80, 88)

Testis, blastocyst, brain,

Insulin-responsive transport in blastocyst;

(75-77, 79,

muscle, adipocytes

glucose, fructose, galactose

80, 94, 95)

Liver, kidney

Glucose, fructose

(75-77, 79,
80, 96-98)

Minor
512
GLUT10

541

0.3

(SLC2A10)

Heart, lung, brain, skeletal

Glucose and galactose

muscle, placenta, liver,

(75-77, 79,
80, 98, 99)

pancreas
GLUT11

496

0.2

(SLC2A11)

Heart, muscle, adipose

Muscle-specific; fructose and glucose

(75-77, 79,

tissue, pancreas

transporter

80, 100104)

GLUT12

617

4-5

(SLC2A12)

GLUT13

Rat 618,

(SLC2A13)

human

0.1

Heart, prostate, skeletal

Glucose

(75-77, 79,

muscle, fat, mammary

80, 103,

gland

105)

Brain (neurons

H+-myo-inositol transporter

intracellular vesicles)

(75-77, 79,
80, 106)

629
GLUT14

Short

unknow

(SLC2A14)

497,

n

Testis

Glucose transport

(75-77, 79,
80, 107)

Long
520
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identification of a molecular clone that encodes an insulin-induced GLUT from mouse
adipocytes (56). It was named GLUT4. Since the 1990s, fluorescent-labeled fusion proteins,
GLUT4-specific antibodies, photoaffinity labeling reagents, immunofluorescence microscopy,
and high-resolution electron microscope have been used to confirm the insulin-induced
translocation and underlying mechanisms (56).
It has been widely accepted that insulin mainly stimulates transfer of GLUT4 from
intracellular storage vesicles to the plasma membrane. Insulin stimulation accelerates the
movement rate of GLUT4 containing vesicles to the cell membrane (108). When more GLUT4
is on the plasma membrane, more glucose enters the cells without any change of the GLUT4
specific activity. During insulin stimulation, GLUT4 is not statically maintained in the plasma
membrane but continuously recycled (56). After insulin is removed, the amount of GLUT4 on
the plasma membrane drops and the rate of movement returns to basal level.
4.3 GLUT4 Gene, its Tissue Distribution, and Physiological Functions
Human GLUT4 has 509 amino acid residues and is encoded by SLC2A4 gene in the human
genome. It is mainly expressed in adipocytes and the skeletal muscle. The unique N- and Cterminal sequences are responsible for GLUT4's response to insulin signaling and membrane
transport (66). The Km of GLUT4 is about 5 mM. In response to insulin stimulation,
intracellular vesicles containing GLUT4 are moved from cytosol to the cell membrane. As
shown in Figure 1-1, insulin receptor is a tetramer with two alpha-subunits and two betasubunits linked by disulfide bonds (109). When insulin binds to its receptor on the cell
membrane, insulin receptor beta subunits with a tyrosine kinase domain autophosphorylate
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each other. The phosphorylated β-subunits recruit insulin receptor substrates (IRS) and
phosphorylate them. Then phosphorylated IRSs bind to and activate phosphatidylinositol 3kinase (PI3K) which is recruited to the plasma membrane and converts PIP2 to PIP3. On the
plasma membrane, PI3K activates PIP3 dependent protein kinase, which phosphorylates and
activates AKT (also referred to as protein kinase B, PKB). AKT activation triggers vesicle
fusion, which results in the translocation of GLUT4 containing vesicles from intracellular
compartments to the plasma membrane. The elevation of GLUT4 on the membrane leads to
increase of glucose entry into the cell.
In the fed state, elevated glucose levels in the blood stimulates insulin secretion from
pancreatic beta cells. Insulin stimulates GLUT4 translocation to the cell membrane, which
increases glucose uptake in cells, and achieves glucose homeostasis (110, 111). After the
insulin stimulation disappears, GLUT4 is transferred back into the cytosol from the plasma
membrane. More than 90% of GLUT4 is in the intracellular body, trans-Golgi network, and
heterogeneous tube-like vesicle structure, etc., which constitute the GLUT4 storage vesicle
(GSV). In an unstimulated state, most GLUT4 is in the intracellular vesicles of muscle and
adipocytes (112).
The amount of GLUT4 on the cell membrane is determined by the rate of the movement
from intracellular GSV to the cell membrane. In adipocytes and skeletal muscle cells, insulin
increases the rate of GLUT4 translocation from GSVs to membrane and decreases the rate of
GLUT4 movement from membrane back to the vesicles, which lead to elevation of GLUT4
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Figure 1-1: Schematic of insulin-induced translocation of GLUT4 from cytosol to the cell membrane. The
binding of insulin to its receptors initiates a signal transduction cascade, which results in the activation of Akt.
Akt acts on the GLUT4 containing vesicles in the cytosol to facilitate their fusion with the cell membrane. When
more GLUT4 molecules are present in the membrane, the rate of glucose uptake is elevated.
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content on the cell membrane by 2-3 times (113). Moreover, in adipocytes, insulin increases
the GLUT4 recirculation to maintain a stable and releasable vesicle (114).
So far, the insulin-induced GLUT4 translocation has been studied extensively. However,
questions remain. Methods and reagents used to determine the expression levels of GLUT4
and its translocation mechanism deserve to be summarized and analyzed. Therefore, we
searched the relevant articles in PubMed and investigated the methods and reagents used in the
studies. “Glucose transporter 4” and “GLUT4” as the protein and “SLC2A4” as the gene name
were used as keywords in the search. To have a more clearly overview, we further focused on
the search of GLUT4 in the skeletal muscle.
4.3.1 GLUT4 in the Skeletal Muscle
Insulin stimulates glucose uptake and utilization in the skeletal muscle. GLUT4 plays a
key role in the uptake process. Glucose can be stored as glycogen, which is used as a quick
source of energy in physical activity (115). In the skeletal muscle, exercise helps increase
insulin sensitivity and stimulates SLC2A4 gene transcription (110). Physiological factors such
as the type of muscle fibers can also affect the GLUT4 level. An increase in physical activity
will induce the GLUT4 levels, whereas a decrease in activity level will reduce GLUT4 (31).
The skeletal muscle not only maintains the activities, but also regulates the glucose homeostasis
in the body, which plays a key role in the development of metabolic diseases (32). Obesity and
T2DM have a negative impact on skeletal muscle glucose metabolism (116).
The skeletal muscle is a highly specialized tissue made of well-organized muscle fibers.
The unique structural characteristic of muscle inherits difficulties to be lysed for biochemical
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studies. Therefore, we want to focus on the sample preparation of skeletal muscle in GLUT4
studies. To review the methods and reagents of GLUT4 studies in skeletal muscle, "GLUT4,
skeletal muscle" and "SLC2A4, skeletal muscle" as keywords were used to search the PubMed
database to retrieve relevant articles. The retrieved articles were screened mainly according to
the research methods and reagents used for skeletal muscle preparation, experimental groups
included, Slc2a4 mRNA and GLUT4 protein measurements and the source of GLUT4
antibodies obtained. In the end, 10 representative articles were selected for analysis and
summary as shown in Table 1-2.
Overall, the current research methods of GLUT 4 studies in the skeletal muscle are listed
below. 1) Samples were homogenized to prepare membrane fractions for analysis of GLUT 4
in Western blot using monoclonal or polyclonal antibodies. 2) Real-time PCR was used to
determine the mRNA abundance of Slc2a4. 3) Immunocytochemical staining was used to
detect GLUT4 in situ. The fibers were labeled for GLUT4 by a preembedding technique and
observed as whole mounts by immunofluorescence microscopy or after sectioning, by
immunogold electron microscopy. Preembedding is a technique to label GLUT4 immediately
after tissues or cells are collected, which allows that the antibody interacts with the antigen
before denaturation. 4) Muscle cell lines stably expressing tagged GLUT4 were established to
study the translocation. 5) Radiolabeled 2-Deoxyglucose was used to determine the glucose
uptake in muscle tissue slices.
The antibodies used in these articles were from Santa Cruz, Millipore, East Acres,
Biogenesis and other sources not specified. Only two of the publications have a positive control
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group of GLUT4 expression using overexpression of a fusion protein and tissue preparation as
a standard for determination. Positive controls are important when Western blot and fusion
protein immunofluorescence methods are used to determine the GLUT4 protein levels.
According to studies summarized in Table 1-2, the following key points can be obtained.
Insulin and muscle contraction increase glucose uptake in the skeletal muscle, which is
associated with increases of GLUT4 content and its translocation (117-119). Neomycin, a
phospholipase D inhibitor, blocks GLUT4 translocation (120). In the skeletal muscle isolated
from GLUT1 transgenic mice, insulin-induced GLUT4 translocation response is lost, which is
not due to down-regulation of GLUT4 expression (121). Conjugated linoleic acid in the diet
does not affect the Slc2a4 mRNA expression in the skeletal muscle (122). Indinavir, an HIV-1
protease inhibitor, can block the glucose uptake mediated by GLUT4 in normal skeletal muscle
and adipocytes with or without insulin stimulation (123). More studies are anticipated to
elucidate how insulin resistance and T2DM affect the functions of GLUT4 system and whether
overnutrition plays a role in it.
4.4 Recombinant DNA Techniques Used in the Studies of GLUT4
Genes in an organism are codes responsible for genetic traits. In most cases, genes usually
exist in the form of nucleotide sequences. In a cell, the DNA sequence of a gene is first
transcribed into mRNA, which serves as the template for protein translation. The newly
synthesized proteins contribute to biological processes in an organism. To understand the
biochemical, biophysical, and genetic functions of a give gene and its protein, recombinant
DNA technologies have been developed and used extensively. Since 1970s, the discovery
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Table 1-2: Recent studies of GLUT4 expression and translocation in the skeletal muscle.
Methods

Materials

Comparisons

Observations/conclusions

References

Western blot.

Cell fractions of rat L6

Cell: total cell lysate

Insulin treatments increases

(117)

myotubes, 3T3-L1, and

vs. membrane

GLUT4 levels in membrane

mouse muscle and adipose

fractions.

fractions without any change

tissues.

Mouse tissues: control

in the total cell lysate.

Anti-GLUT4 from Santa

vs. high-fat diets.

GLUT4 levels in adipose

Cruz Biotechnology

tissue and muscle of mice

(1:1,000).

fed a high-fat diet are lower
in all fractions than that fed
the control diet.

Western blot.

Whole cell and cell fractions

Whole cell lysate vs.

GLUT4 translocation occurs

from rat L6 and mouse

membrane fractions.

in L6 myotubes and 3T3‐

C2C12 muscle cells, and

Treatments without or

L1 adipocytes stimulated by

soleus muscle of hind limb

with insulin or

insulin and AICAR. GLUT4

from mice.

AICAR.

translocation occurs in

Anti-GLUT4 from Santa

muscle at 15 to 30 minutes

Cruz. Biotechnology

and in adipose tissue at 15

(1:1,000).

minutes after glucose

(119)

treatment.
Western Blot.

Giant sarcolemmal vesicles

Tissue samples

A glucose-dependent

from soleus muscles of

without or with insulin

insulinotropic polypeptide

Sprague-Dawley rats.

released in the

increases glucose transport

Anti-GLUT4 from Millipore

presence of glucose as

and plasma membrane

(1:4,000).

a stimulant and lipid as

GLUT4 protein content.

(118)

a control.
Real-time PCR for

Total RNA of the skeletal

mRNA levels in

Dietary CLA does not affect

Slc2a4 mRNA

muscle from male C57BL/6J

muscle samples from

Slc2a4 mRNA levels in the

levels.

and ICR mice fed different

mice fed the control or

mouse skeletal muscle

diets.

CLA supplement diet

Preparations of sarcolemmal

GLUT4 from a unique

Polyclonal antibodies detect

membrane fractions and

crude membrane

a protein of similar size (∼45

crude lysates from male

fraction of rat skeletal

kDa) of GLUT4 in the crude

Muscovy ducklings.

muscle was used as an

membrane preparations

Anti-GLUT4 from East

arbitrary unit and from

from rat (positive control)

Acres (1:500).

erythrocyte ghost as a

and duckling skeletal

negative control

muscle. No signal was

Western blot.

obtained for rat erythrocyte
ghost membrane
preparation.
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(122)

(124)

Table 1-2 Continued
Methods

Materials

Comparisons

Observations/conclusions

References

ATB-BMPA-

Tissue samples of isolated

Non-transgenic mice

Basal levels of cell-surface

(121)

labelling of

and perfused EDL or soleus

vs. transgenic mice.

GLUT4 in isolated or

glucose

muscle from GLUT1

perfused EDL are similar in

transporters,

transgenic C57BL’KsJ-

transgenic and non-

Immunoprecipitati

Leprdbj and control mice.

transgenic mice. Insulin

on, liquid-

Anti-GLUT4 (R1184; C-

induces cell-surface GLUT4

scintillation

terminal) from an unknown

by 2-fold in isolated EDL

counting, Western

source.

and by 6-fold in perfused

blot.

EDL of both transgenic and
non-transgenic mice.
Western blot results were
not shown.

Preembedding

Muscle samples from male

Rats were divided in

Two populations of

technique

Wistar rats.

four groups: control,

intracellular GLUT4

(immune reaction

Anti-GLUT4 (C-terminal,

contraction received

vesicles are differentially

occurs prior to

1:1,000), and anti-GLUT4

saline, insulin and

recruited by insulin and

resin embedding

(13 N-terminal, 1:500) from

insulin plus

muscle contractions. The

to label GLUT4),

unknown species.

contraction groups.

increase in glucose transport

and observations

They received glucose

by insulin and contractions

of whole mounts

followed by insulin

in the skeletal muscle is due

by

injection.

to an additive translocation

immunofluorescen

to both the plasma

ce microscopy, or

membrane and T tubules.

after sectioning by

Unmasking of GLUT4

immunogold

COOH-terminal epitopes

electron

and changes in T tubule

microscopy.

diameters does not

(125)

contribute to the increase in
glucose transport.
Immunoprecipitati

Membrane fractions from

Crude membrane

In vitro activation of PLD in

on, and Western

skeletal muscle of male

preparations and

crude membranes results in

blot.

Wistar rats treated without

cytosolic fractions in

movement of GLUT4 to

or with insulin.

samples of rats treated

vesicles/microsomes. This

Anti-GLUT-4 from

without or with

GLUT4 translocation is

Genzyme, Anti-GLUT-4

insulin .

blocked by the PLD

from Santa Cruz

inhibitor, neomycin, which

Biotechnology.

also reduces insulinstimulated glucose transport
in rat soleus muscle.
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References

Western blot for

Muscle homogenate and

Sedentary control vs a

The change of insulin

(126)

GLUT4 protein in

slices from male Sprague-

5-day swimming

responsiveness after

homogenates of

Dawley rats.

training group.

detraining is directly related

epitrochlearis

Anti- GLUT4 from Dr.

to muscle GLUT-4 protein

muscles.

Osamu Ezaki.

content.

Tissue slices

The greater the increase in

labeled with 2-

GLUT-4 protein content

3

[1,2- H]-deoxy-d-

induced by training, the

glucose and

longer an effect on insulin

counted in a

responsiveness lasts after

gamma counter.

training.

Immunofluorescen

Membrane preparations

L6 cells over-

HIV-1 protease inhibitor

ce for membrane

from L6 cells over-

expressing

indinavir at 100 µmol/l

preparations, and

expressing GLUT4myc.

GLUT4myc treated

inhibits 80% of basal and

2-Deoxyglucose

Isolated skeletal muscle

without or with

insulin-stimulated 2-

uptake in isolated

samples from mice.

Indinavir.

deoxyglucose uptake in L6

skeletal muscles.

Anti-GLUT4 from

myotubes with stable

Biogenesis.

expression of GLUT4myc.

(123)

Note: AICAR, 5-aminoimidazole-4- carboxamide ribonucleotide; CLA, conjugated linoleic acid; EDL, extensor
digitorum longus; HIV, human immunodeficiency virus; ICR, institute of Cancer Research; PLD, phospholipase
D.
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of restriction enzymes has allowed the manipulation of DNA sequences selectively and
specifically to create novel recombinant molecules (127). Molecular cloning methods have
been created to insert DNA fragments into vectors to form recombinant genetic materials for
functional studies and productions of recombinant proteins. The vectors carry the recombinant
DNA and replicate it for subsequent uses. The first recombinant DNA molecule was produced
and studied in 1972 after the genes responsible for metabolism of galactose in E. coli were
fused into the SV40 DNA genome (128). For the past few decades, procedures of molecular
cloning have been simplified and standardized to construct recombinant DNA with various
sizes for different purposes (129). All these have been applied to generate transgenic organisms
and produce recombinant proteins for the use in variety of research and clinical settings.
The development of molecular cloning techniques allows isolation, generation, and
production of DNA sequence independence of the species and organisms that carry the original
sequences. DNA fragments can be isolated from genomes or created via polymerase chain
reaction (PCR) using a template of cDNA or genomic DNA, and inserted into vectors that can
replicate and express in the host cells, and in turn alter the genetic features of the host cells,
tissues or organisms (130). The development of PCR technique facilitates molecular cloning
tremendously as it produces many copies of a specific DNA sequence in a few hours instead
of days.
4.4.1 The Common Cloning Techniques
Restriction enzyme-based cloning is the traditional cloning technology, which is currently
the most widely used cloning technology. The gene of interest is inserted into the vector by
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enzyme digestion and DNA ligation. The main advantage is that the technology is stable; the
disadvantage is that the errors in any link will affect the success or failure of the clone
construction because of multiple steps. Ligation Independent Cloning (LIC) is a technique
developed as an alternative to restriction enzyme/ligase cloning. Inserts are usually PCR
amplified and vectors are made linear either by restriction enzyme digestion or by PCR. This
creative technique uses the 3’ → 5’ exo activity of T4 DNA Polymerase to create overhangs
with complementarity between the vector and insert (131). The 5' sequence of the primer used
to amplify the insert should be complementary to the LIC vector. The 3'→5' exonuclease
activity of T4 DNA polymerase can form a single-stranded sticky end on the insert in a short
time, then stopped by adding dCTP to the reaction. Since the prepared insert and the vector can
only anneal to each other to form a product, this method is very fast and efficient, and it is
directional cloning. Due to the complexity of its operation and the limitation of use, it has
evolved to many useful variations; sequence and ligation independent cloning is one of the
useful variation (131). Seamless cloning (SC) technology is similar to LIC and relies on
matching the short sequence at the end of the DNA fragment with the short sequence on the
plasmid vector (132).
TA cloning must use a commercial linearized vector. There is a thymine (T) at the 3´ end
of the linear vector, which exactly matches the adenine (A) at the 3´ end of the PCR amplified
product. These complementary base pairs on different DNA fragments are ligated together
using Taq DNA ligase. The biggest advantage of this cloning is that the vector is easy to use,
and the amplified product can be cloned directly into the vector. Similar as TA cloning, the key
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to TOPO cloning is the enzyme DNA topoisomerase I, which functions both as a restriction
enzyme and as a ligase. It can digest DNA at specific site 5’-(C/T)CCTT-3’ and ligates at 3’
phosphate group of thymidine base (133).
Gateway cloning is a molecular cloning technology that uses specific primers to insert
specific gene sequences on both sides of the desired gene by PCR. Gateway cloning uses two
enzyme mixtures, BP Clonase and LR Clonase. The gene is cloned into an entry vector using
BP Clonase, and then this entry clone is used to transfer the gene to the expression vector
through LR Clonase (134). Golden Gate cloning is a method that relies on type II restriction
enzymes, the plasmid contains type II restriction sites or is amplified by PCR to add type II
restriction enzyme sites. Type II restriction sites are eliminated after enzymatic ligation and
will not appear in the final vector. Therefore, this is an irreversible gene assembly method.
Once the gene is inserted into the vector, it can never be cut with the same restriction enzyme
(135). Infusion cloning is a simple one-step cloning technique that amplifies genes by PCR
with 15bp extension complementary to the vector ends and clones the PCR products into
linearized vector without ligation (136). Table 1-3 summarizes common cloning methods
including restriction enzyme-based cloning, LIC, SC, TA cloning, TOPO cloning, gateway
cloning, infusion cloning, golden gate cloning.
In addition, large numbers of DNA copies obtained in recombinant DNA technologies can be
used for sequencing analysis and further subcloning procedures. Knowing the DNA sequences
allows us to explore its biological functions. It also allows preparations of large amounts of
protein, such as growth hormone, insulin and clotting factors for therapeutic purposes (137).
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DNA sequences of different organisms can be compared to determine the evolutionary
relationship within and between species (138). Functional regions of a gene can be identified
after the sequences are compared (27). Recombinant DNA technologies can be used in gene
therapies to treat diseases such as immunodeficiency diseases and metabolic disorders (139)
and diagnosis of genetic diseases (140).
The basic molecular cloning procedure includes vector preparations and isolations of
target DNA fragments (DNA inserts), ligation of insert fragments with vectors to create
recombinant molecules, transformation of recombinant plasmids into bacteria (such as
competent E. coli) for the screen and identification of positive clones. The cloned DNA
fragments can be further manipulated to create mutations for the study of protein and gene
functions. The mutated DNA fragment is inserted into cells or organisms, replaced the wildtype sequence of the gene, and used to investigate the effects of the mutation. For example, the
altered DNA sequence can be used for gene knockout, in which only the targeted gene sequence
is changed in a genome (27).
4.4.2 The Gene Knockout Techniques
Genetically modified organisms or genetically engineered organisms can be created via
alterations of the genetic sequences of the chromosome or insertions of the foreign DNA
fragments into the genome to alter the phenotypes of the offspring (141). Genes in plants,
animals and microorganisms have been deleted or knocked down to investigate their functions
(142). It is applied to research in labs, and clinical treatments of genetic diseases. There are
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Table 1-3: Comparison of different gene cloning methods
Enzymes
Restriction

Restriction

enzyme based

enzyme, T4

cloning

DNA ligase

Ligation
independent
cloning (LIC)

T4 DNA
Polymerase

Recombinant
Seamless
cloning (SC)

enzyme, equires
a DNA
polymerase and
a DNA ligase

TA cloning

T4 DNA ligase

Advantages

Disadvantages
Low cloning efficiency, difficulty in
selecting restriction sites, many

High cost performance

steps, long operating time, limited
experimental applicability

Not restricted by restriction
sites, multi-fragment

Low cloning efficiency

ligation

Simple, flexible, efficient,
allows insertion of multi-

High primer synthesis cost

DNA fragment into a
vector

The carrier construction

Only TA cloning can be performed,

connection is directional,

enzyme cutting site is required,

multi clones, can used for

positive rate low, steps are

cloning or vector

cumbersome and need to recycle

construction

fragments, time consuming

Very efficient, simple and
TOPO cloning

Applications

Topoisomerase

fast, don’t need to use

I (TI)

restriction enzymes or

Specific primers are needed,
efficiency of cloning can vary
depending on the polymerase used

ligase
BP (attB sites
and attP sites)

Limited by vector carrier, enzymes

Gateway

Clonase, LR

High throughput cloning,

expensive and unstable, the steps are

cloning

(attL sites and

fast, efficient

cumbersome, connection of 1-4

attR sites)

fragments

Clonase
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Highthroughput
construction

Table 1-3 Continued
Enzymes

Advantages

Disadvantages

Applications

Simple, fast, efficient, can
Infusion
cloning

Specific

cloning with any vector

infusion

and any gene fragment,

enzyme

does not rely on restriction

The vector and the insert must
overlap by 15bp

linearized
cloning
vector

enzyme sites for cloning.

Type II
Golden Gate

restriction

High-throughput cloning,

Limited by vector carrier, limited

CAS9 vector

cloning

enzymes, T4

multi-fragment ligation

range of applications

construction

DNA ligase
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several methods that can be used to silence or remove the target gene, such as gene silencing,
conditional knockout, homologous recombination, and gene editing (66, 142). Homologous
recombination occurs in cells to produce new DNA sequence during meiosis (143). This has
been used to exchange genetic materials between different strains and types of bacteria and
viruses (143). Homologous recombinases (nucleases) can recombine two linearized nucleotide
fragments with the same terminal sequences to create a novel DNA fragment for molecular
manipulations (144). This makes accurate gene editing possible and becomes emerging tools
in genetics (145). Various nucleases based gene knockout technologies, such as zinc finger
nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and clustered
regularly interspaced short palindromic repeat (CRISPR) are developed and shown differences
in knockout efficiency, completion time, and off-target efficiency (142) (Table 1-4). Each of
these techniques uses a nuclease to introduce DNA double-strand breaks at the targeted
locations with the guidance of homologous binding proteins or RNA (146).
4.4.3 The Gene Knockdown Techniques
Gene knockdown is to inactivate or suppress the expression of the gene, instead of being
deleted completely. RNA-based RNA interference, small interfering RNA (siRNA) and short
hairpin RNA (shRNA), and antisense oligonucleotides (ASOs) have been used for gene
knockdown (147). RNA interference (RNAi) is triggered by double-stranded RNA and causes
the sequence-specific mRNA degradation of the single-stranded target RNA (148). Small noncoding RNA molecules can also act to inhibit RNA translation (149). Table 1-5 shows the
similarities and differences of shRNA, siRNA and ASOs are summarized.
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Table 1-4: Comparison of ZFNs, TALENs, and CRIPR/Cas9
ZFNs

TALENs

CRISPR/Cas9
easy to generate, higher

Advantages

High specificity, low

Modular assembly, less

target efficiency, ability to

immunity

cytotoxic effects

multiply for targeting of
multiple genes

Difficult to predict
cytotoxic effetcs, required
Disadvantages

to target specific DNA
sequence, target site choice
limited

Difficult to constructs,
large protein size, binding
is negatively impact by
DNA methylation

Higher off-target effects,
biding efficiency impacted by
chromatin accessibility

Target specificity

Zinc Finger proteins

TALEN

Cas9 nuclease, gRNA

Target

Pair

Pair

Single

Target site size (bp)

18-36

30-40

22

Guiding sequence

Protein

Protein

gRNA

FokI, single strand

FokI, single strand

cleavage

cleavage

Variable

High

Nuclease and Cleavage
Efficiency

Cas9, double strand cleavage
High

Note: Cas 9, CRISPR associated protein 9; gRNA, guide RNA.
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Table 1-5: Summarized of small interfering RNA (siRNA) or short hairpin RNA (shRNA)) and antisense
oligonucleotides (ASOs)
Small interfering RNA

Short hairpin RNA

Antisense oligonucleotides

(siRNA)

(shRNA)

(ASOs)

Delivery to the cell

Cytoplasm

Nucleus

Nucleus

Range

Approximately 20 base

Approximately 19 to

Approximately 18 to 30 base

pairs (bp)

29 base pairs (bp)

pairs (bp)

Degraded in a few days

Expressed for up to

Could be rapidly digested

Persistence

a few years
Advantages

Can be easily introduced

High transduction

Can knockdown nuclear long

into cells with high

efficiencies,

non-coding RNA.

efficiency, easily fast to

transduced cells can

use, less off-target

be selected through

effects.

drug resistance or
reporter. long term
effect

Disadvantages

Non-renewable resource,

Virus-mediated

Less effective to cytoplasmic

cells might not be

toxic effects

long non-coding RNA,

transfectable, short term

higher off-target effect

effect.
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In addition to deletion or inactivation of a gene, recombinant DNA techniques have been
used to generate tagged proteins or fusion proteins with novel properties (150). A fusion protein
contains two or more domains from different proteins, which are transcribed and translated in
frame as a single polypeptide in the targeted cell or tissues. The characteristics of fusion
proteins are helpful for protein purification for their uses in research and clinical treatments,
detection of the expression levels, and visualization of the location of the expressed proteins in
a cell, tissue, or organism (151). These have been used to create vaccines, multifunctional
enzymes, targeted drugs, thrombolytics, antimicrobial peptides, etc (152).
4.4.4 Molecular Techniques Used in the Study of GLUT4 Functions
GLUT 4 is encoded by SLC2A4 in human genome and Slc2a4 in others such as rodent
genomes (153). Slc2a4 is cloned from rat adipose tissue, and is homologous with GLUT1,
which is encoded by Slc2a1 gene (154-156). GLUT4 is expressed in not only adipose and
muscle cells, but also other tissues such as the heart and brain (157). The current model is that
in response to insulin stimulation, GLUT4 is translocated from the intracellular locations to the
plasma membrane, where it facilitates the transport of glucose into cells (158). In addition,
exercise has been shown to stimulate the express of SLC2A4 mRNA in the skeletal muscle and
improve insulin sensitivity in patients (159), which may be mediated by GLUT4 (160). Insulinstimulated glucose transport is significantly impaired in the skeletal muscles of patients with
T2DM (161). Therefore, understanding the role of GLUT4 in the regulation of glucose
homeostasis is critical for the prevention and treatment of T2DM.
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Here, we summarize the recombinant DNA technologies that have been used to study
expression profiles and functions of GLUT4 in tissues and cells. Key words as indicated in the
following sections were used to search PubMed. The methods used to manipulate the
expression levels of GLUT4 in vivo and in vitro and reported observations in retrieved studies
were summarized here.
GLUT4 overexpression and knockdown, and Slc2a4 gene knockout in vitro and in vivo
have been developed to study insulin-stimulated GLUT4 translocation and glucose
homeostasis, which contribute significantly to our understanding of the role of GLUT4 (56).
To review the techniques of molecular biology in the study of GLUT4, "GLUT4, molecular
biology" and "SLC2A4, molecular biology" as keywords were used to search the PubMed
database to retrieve relevant articles. We have focused on the techniques used in Slc24a
knockout, knockdown and transgenic studies, and results associated with the genetic changes
in vivo and in vitro. Various methods such as in situ hybridization, fluorescent microscopy,
immunohistochemistry, Western blotting for protein and Northern blot and real-time PCR for
mRNA used to determine endogenous or transgenic GLUT4 expressions are also summarized
in this review.
4.4.4.1 Whole-body and Tissue Specific Slc2a4 Knockout Studies
Slc2a4 mRNA expression is detected not only in brown and white adipose tissue, skeletal
and cardiac muscle, but also other tissues such as neurons (162). To study GLUT4 functions,
mice with the Slc2a4 deletion in the whole body or specific tissues or cells have been created.
We searched PubMed to retrieve the original articles that initially reported the Slc2a4 deletions.
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Table 1-6 shows the techniques for creating knockouts, experimental animals, methods to
confirm the gene deletion and expression, and observations. In the end, 7 representative articles
that the research groups generated a specific knockout model to study GLUT4 and clearly
describe the methods of GLUT4 deletion are summarized here as shown in Table 1-6. Also,
the animal models were also used by many other groups. These articles were selected for
analysis and summary as shown in Table 1-6.
In1995, the mouse Slc2a4 locus was disrupted using homologous recombination in
embryonic stem cells and have generated mice without GLUT4 expression (GLUT4-null) in
the whole body (163). The GLUT4-null mice showed growth retardation, enlarged hearts and
complete lack of white adipose tissue (163). GLUT4-null mice have normal glucose tolerance
and basal glucose turnover rates. However, they are insulin intolerant, suggesting insulin
resistance. Later on, the GLUT4-null mice (163) have been used to create mice expressing
GLUT4 specifically in the extensor digitorum longus (EDL) muscle (164).
Tissue specific GLUT4 knockout mice have been created by crossing mice carrying a Slc2a4
allele with exon 10 flanked by loxP sites with those carrying Cre driven by tissue specific
promoters (165-168). The various phenotypes of these knockout mice help us to understand
the roles of GLUT4 in different tissues and glucose metabolism. For example, the musclespecific GLUT4 knock-out mice (muscle-G4KO) were bred by breeding mice carrying the
Slc2a4 exon 10 flanked by loxP sites with mice carrying a transgene encoding Cre recombinase
under the control of the muscle creatine kinase promoter (166). Compared with GLUT4-null
mice, muscle-G4KO mice have normal body weight and fat pad weight at least before 6 months
39

of age (166). The skeletal muscle mass is also normal. The increase in heart weight is consistent
with GLUT4-null mice (163) and cardiac-G4KO mice (165). Compared with the shortened
lifespan of GLUT4-null mice, the life span of muscle-G4KO mice is normal. In contrast to
GLUT4-null mice and cardiac-G4KO mice, adipose-G4KO mice (167) is similar as muscleG4KO mice. However, adipose-G4KO mice have glucose intolerance (167). Interestingly,
unlike other GLUT4 knockout mice, the heart weight of adipose-G4KO mice is normal.
In addition, adipose and muscle double knockout mice are also created by crossing the
respective tissue knockout mice (169). Interestingly, these double knockout mice develop
hyperglycemia in the fasting state (169). It appears that GLUT4 also plays a role in a
physiological condition that does not need insulin-stimulated glucose uptake.
4.4.4.2 GLUT4 Knockdown Studies
The deletion of a gene completely stops the genetic information flow. Another way to
block the protein expression is to knockdown a gene’s expression, which temporarily stops or
reduces the expression of the targeted gene. Unlike knockout, gene knockdown involves the
methods interfering with RNA molecules (mRNA or non-coding RNA) that bridges DNA and
proteins. "GLUT4, knockdown" and "SLC2A4, knockdown" as keywords were used to search
the PubMed database to retrieve relevant articles. Table 1-7 summarizes the methods of
knockdown and confirmation, cell used, observations of GLUT4 knockdown studies.
Recently, RNAi has emerged as a powerful tool for the study of gene function in
mammalian cells (170). After transfection, the short hairpin RNAs (shRNAs) molecules are
transcribed under promoters in constructs that drive the RNA synthesis within the targeted cells.
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Table 1-6: Methods of creation and confirmation, animals and tissues studied, and observations of whole
body and tissue specific Slc2A4 knockout.
Methods

Animals

Confirmation

Tissues

Observations

References

Homologous

GLUT4-null mice

Southern blot for

Skeletal

The Slc2a4-/-mice have

(163)

recombination was

and wild-type

DNA from ES cells

muscle

normal glycemia, and show

initiated using a

control mice.

and animal tissues.

linearized construct

growth-retardation,
decreased longevity,

Northern blot for

containing a

cardiac hypertrophy and

mRNA in the

disrupted mouse

severely reduced adipose

skeletal muscle.

Slc2a4 gene and

tissue deposits.
Western blot for

electroporated into

The male Slc2a4-/-mice

GLUT4 protein in

WW6/22 embryonic

have lower and higher

the skeletal muscle.

stem (ES) cells,

blood glucose levels than

which were

the control ones in fasted

microinjected into

and fed states, respectively.

C57Bl/ 6
Both female and male

blastocysts.

Slc2a4-/- mice show
postprandial
hyperinsulinemia, and
reduced insulin sensitivity.
GLUT4 loxP mice

Cardiac-selective

Southern blotting

containing an 18-kb

Slc2a4-/-deletion

and PCR for DNA

of insulin, glucose, FFAs,

fragment of the

mice (G4H–/–

changes.

lactate, and β-

coding region of

mice) and control

Slc2a4 gene (from a

mice

mouse 129 λ
bacteriophage
library) were
crossed with mice

Heart

Life span and serum levels

hydroxybutyrate are

Western blot

normal in G4H–/– mice.

analysis for GLUT4
levels in cardiac

Basal cardiac glucose

muscle using

transport and GLUT1

antisera from

expression are increased,

different sources.

but insulin-stimulated

containing cre

glucose uptake is abolished

recombinase driven

in G4H–/– mice, which

by α-myosin heavy-

develop modest cardiac

chain (α-MHC)

hypertrophy.

promoter
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Table 1-6 Continued
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Tissues

Observations

References

Mice carrying a

Muscle-G4KO

Reverse

Skeletal

Muscle-G4KO mice show

(166)

Slc2a4 allele with

mice and

transcription–PCR

muscle

a reduction in basal and

exon 10 flanked by

heterozygous

for mRNA in

near-absence of insulin- or

loxP sites

deletion of Slc2a4

gastrocnemius

contraction-stimulated

(GLUT4lox mice)

(Het KO mice) in

muscle.

glucose transport.

as shown in (165)

the background of

Western blot for

Muscle-G4KO mice show

were crossed with

129SV and

GLUT4 protein

severe insulin resistance

mice carrying the

C57Bl/6J.

(anti-GLUT4

and glucose intolerance

AB1346).

from an early age.

transgene encoding
Cre driven by the
muscle creatine
kinase promoter.
The MLC-GLUT4-

MLC-GLUT4-null

Western blot for

EDL

MLC-GLUT4-null mice

null mice were

mice having

GLUT4 protein

muscle

lack GLUT4 in white

obtained by

GLUT4 in the

(rabbit polyclonal

and

adipose tissue (WAT, 20%

crossing GLUT4-

fast-twitch

antiserum).

soleus

of the control) of female

null mice with

extensor digitorum

muscle

mice and soleus muscle of

transgenic mice

longus (EDL)

expressing GLUT 4

muscle, GLUT4

under the control of

null mice, and

the myosin light

control mice.

(164)

both sexes.
The MLC-GLUT4-null
mice have less adipose
tissue deposits, adipocyte

chain (MLC)

size, and plasma free fatty

promoter (MLC-

acid levels in the fed state.

GLUT4) (171).
2-deoxyglucose uptake in
the EDL muscle of MLCGLUT4-null mice is
normalized in males and
above normal in females,
but not in the soleus
muscle.
GLUT4–lox mice

Mice with

Western blot for

Adipose

G4A-/- mice have impaired

were crossed

adipose-selective

GLUT4 protein in

tissues

insulin-stimulated glucose

transgenic mice

deletion of

brown adipose tissue

uptake in adipocytes, and

expressing Cre

GLUT4 (G4A-/-),

(BAT) and WAT

develop glucose

recombinase under

and control mice

intolerance and

the aP2 promoter to

hyperinsulinemia, and

obtain GLUT4

show insulin resistance in

(G4A-/-)

the muscle and liver.
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Observations

References

The adipose-

Adipose-GLUT4-

Western blot for

Adipose

AMG4KO mice develop

(169)

GLUT4-KO mice

KO mice, muscle-

GLUT4 protein

tissue

fasting hyperglycemia and

(167) were crossed

GLUT4-KO mice,

using antibodies

and the

glucose intolerance and are

with the muscle-

and AMG4KO

from H. Haspel in

skeletal

at risk for greater insulin

GLUT4-KO mice

mice.

the Charles River

muscle

resistance than mice

(166) to generate

Laboratory.

lacking GLUT4 in only

adipose/muscle-

one tissue.

GLUT4 double
knockout
(AMG4KO) mice
Mice expressing

BG4KO and

Western blot for

Whole-

BG4KO mice have glucose

Cre driven by the

control mice

GLUT4 protein in

brain

intolerance, insulin

neuron-specific

brain (1:1,000, from

tissue

resistance, and impaired

Nestin promoter

Chemicon,

glucose sensing, indicating

were crossed with

Temecula, CA)

that the brain GLUT4 plays

GLUT4–lox mice

a key role in sensing and

(FVB strain) to

responding to changes in

generate brain-

blood sugar.

specific GLUT4
knockout (BG4KO)
mice
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Oligo nucleotides with sequences of shRNAs may be transfected directly into the cells (170).
In all studies summarized in Table 1-7, shRNAs method is used to achieve GLUT4 knockdown
(172-174), which is delivered via recombinant retroviruses. Two of three studies investigated
the roles of GLUT4 in 3T3-L1 adipocytes. It appears that GLUT4 expression is needed for the
lipogenesis after differentiation in 3T3-L1 cells but not necessary for lipogenesis during
differentiation (174). In addition, insulin-regulated aminopeptidase (IRAP) trafficking is not
always associated with the GLUT4 movement (173).
4.4.4.3 GLUT4 Transgenic Studies
We have used key words “GLUT4 transgenic” (314 hits) results when and “GLUT4
overexpression” (609 hit) to search PubMed to retrieve GLUT4 transgenic studies. After going
through the titles or abstracts containing “GLUT4 overexpression/ GLUT4 transgenic”, we
found 15 papers that have described their original methods or clearly cited the methods used
by them, confirmed the GLUT4 overexpression in mice and provided results. Table 1-8
summarize the techniques used to overexpress GLUT4, the methods to confirm the expression
and results observed in those animals.
In 1992, a 2.4-kb fragment of 5’ flanking DNA of human SLC2A4 promoter fused with
the bacterial chloramphenicol acetyltransferase (CAT) as a reporter construct was developed
and used as a reporter to indicate the SLC2A4 expression in mice (175). In 1993, an 11.5-kb
SLC2A4 mini gene in pHSS6 vector was created and used to overexpress human GLUT4 in
the whole body of mice (176). As shown in Table 1-8, the mouse line containing the 11.5-kb
mini gene has been used in 7 out of 8 papers testing the effects of overexpression of human
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Table 1-7: Methods of creation and confirmation, cells used, observations of GLUT4 knockdown studies.
Methods

Cells

Confirmation

Observations

Recombinant

Human head and neck

Western blot for

The knockdown of GLUT4

lentivirus was

squamous cancer cell

GLUT4 protein

expression in HSC-2 cells leads to

created to express

lines, HSC-2 and

(Epitomics,

elevated DEXD-H-box helicase 58and

short hairpin RNA

HSC-3-M3

Cambridge,

2′-5′-Oligoadenylate synthetase Like

MA, USA)

expressions.

(shRNA) using
SLC2A4 sequence

The cells with GLUT4 knockdown

(NM_001042.3)

decrease migratory ability.

Recombinant

Immunofluoresc

GLUT4 knockdown does not affect

retroviruses were

ence of phase-

insulin-regulated aminopeptidase

created using

contrast and

(IRAP) trafficking, demonstrating that

pSIREN RetroQ

epifluorescence

IRAP traffics is independent of

system to produce

images for

GLUT4.

shRNAs

GLUT4 protein

corresponding to

using antibodies

mouse Slc2a4

(rabbit anti-

sequence

GLUT4, a gift

GGTGATTGAA

from Dr. Sam

CAGAGCTAC

Cushman

(GenBank ID was

(National

not specified by

Institutes of

authors) .

Health).

Recombinant

3T3-L1 adipocytes

3T3-L1 adipocytes

Immunofluoresc

In GLUT4 knockdown 3T3-L1

lentivirus-

ence

adipocytes, insulin-stimulated glucose

mediated shRNA

microscopy and

uptake was only reduced by 50-60%.

under the control

Western blot for

of

GLUT4 (rabbit

human H1-RNA

anti-GLUT4

promoter was

polyclonal

created using the

antibody, from

mouse Slc2a4

Chemicon

mRNA sequence

International

(GenBank ID was

Inc. (Temecula,

not included).

CA))

GLUT4 knockdown leads to impaired
expression of IRAP depending on
whether GLUT4 is knocked down
during the differentiating or
differentiated stage.
The knockdown reduces the complete
lipogenic capacity of differentiated
adipocytes, but not lipogenesis during
differentiation.
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References
(172)

(173)

(174)

GLUT4 in the mouse whole body on metabolism (176-182). CAT activity, SLC2A4 mRNA
and/or GLUT4 protein level in adipose tissue and skeletal muscle and other tissues have been
analyzed to confirm the success of the transgenic expression (176, 177). In general, the wholebody human GLUT4 overexpression reduces blood glucose in both fasting and fed states and
increased glucose uptake in mice but affects the blood insulin level in wild type mice and
diabetic mice differentially (177). Whole body GLUT4 overexpression do not alter body weight
but can reduce blood glucose level and affect serum insulin level.
GLUT4 has been overexpressed in a tissue specific manner as shows in Table 1-9.
Majority of the studies been focused on adipose tissues (183-187). There is one in the skeleton
muscle (171) and one in adipocytes (188). A 6.3-kb genomic DNA fragment of human SLC2A4
gene driven by the mouse ap2 (183) promoter has been used to overexpress GLUT4 in mouse
adipose tissues. This method was first published in 1993 (183) and was used in many other
studies in the genetic settings of wild-type mice and diabetic mice (184-187). Like the papers
summarized in the Table 1-9, a human SLC2A4 gene under a tissue-specific promoter was used
to overexpress GLUT4.
Human SLC2A4 cDNA was also used to overexpress GLUT4 in adipocytes (188), but
mouse Slc2a4 gene was used to express GLUT4 in the hindlimb muscle (171). All adipose
tissue specific GLUT4 overexpression studies (171, 183-187) tested the SLC2A4 mRNA or
GLUT4 protein level to confirm GLUT4 expression, which is found to be expressed in both
brown and white adipose tissues.
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Table 1-8: The transgenic studies using the SLC2A4 mini gene and its promoter for the whole-body
expression in mice.
Constructs

Confirmation

Results

References

A 11.5-kb mini gene of

GLUT4 mRNA and protein

The hGLUT4-11.5kb mRNA expression was detected

(176)

human SLC2A4 starts with

overexpression in both adipose

in white and brown adipose tissue, heart and skeleton

a 5.3-kb fragment upstream

tissue, heart and skeleton

muscle of the transgenic mice.

of transcription start and

muscle via RNase protection

terminates within exon 10

assay and Western blot,

of the gene followed by the

respectively.

bacterial chloramphenicol

Compared to that in the control mice, GLUT4 protein
level is increased in adipose tissue, liver, heart and
skeleton muscle. Female transgenic mice have higher
GLUT4 protein in the adipose tissue and less SLC2A4

acetyltransferase (CAT) in

mRNA in skeleton muscle than male ones.

pHSS6 vector.
The 11.5-kb minigene with

SLC2A4 mRNA overexpression

Compared to the control diabetic mice, transgenic

the CAT marker as shown

in cardiac and hindquarter

diabetic mice grew similarly for 10 weeks of age when

in (176).

muscle, brown and white

the control mice stopped gaining weight, whereas

adipose tissue via reverse

transgenic mice continued until 15 weeks old; have

transcription PCR.

lower blood glucose in both fasting and fed states; have

(177)

lower serum insulin level during fasting and higher after
refeeding; and higher glycogen levels in cardiac and
Immunofluorescent test for
GLUT4 translocation.

skeleton muscle; higher GLUT4 translocation and cell
surface GLUT4 protein content.

The 11.5 kb minigene with

GLUT4 overexpression in

Compared to the control mice, transgenic mice have

the CAT marker as shown

gastrocnemius muscles via

lower serum glucose level in both fasting and fed state,

in (176).

Western blot.

higher insulin level during fasting and lower after fed,

(178)

and similar glycogen content in fasting and fed state.
The 11.5 kb minigene with

GLUT4 overexpression in heart

Compared to the control mice, transgenic mice have

the CAT marker as shown

via Western blot.

increased glucose uptake, glycolysis and glycogen

in (176)

(179)

content, but not glucose and fatty acid oxidation in the
heart, and lost insulin-stimulated glycolysis rate and
glycogen synthesis.

The 11.5 kb minigene with

GLUT4 protein overexpression

Compared to the control mice, transgenic mice have

the CAT marker as shown

in muscle, brown and white

similar body weight; increased levels of triglycerides,

in (176)

adipose tissue (no data shown)

beta-Hydroxybutyrate and free fatty acids; parametrial,

GLUT4 protein overexpression
in cardiac myocyte and
adipocyte via
Immunofluorescence

but not epididymal, adipose tissue weight and adipocyte
cell size; and significantly lower glucose level after an
oral glucose challenge; lower insulin level after an
insulin injection, and impaired insulin-stimulated
glucose uptake.
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(180)

Table 1-8 Continued
Constructs

Confirmation

Results

References

A 2.4-kb of 5’ flanking

CAT activity and mRNA

In transgenic mice, CAT activity can be detected in the

(175)

DNA fragment of human

via RNase protection

tissues that generally express GLUT4, including white

SLC2A4 promoter fused

assay.

and brown tissue, smooth, skeleton and cardiac muscle,

with the CTA as a reporter

but not the liver.

construct.
The authors cited the paper

GLUT4 overexpression in

Compared to the control mice, transgenic mice have

that described a 2.4-kb of

both adipose and skeleton

reduced rises of blood glucose, but no different in glucose

5’ flanking DNA of human

muscle via Western blot.

and insulin levels during pentobarbital sodium anesthesia;

SLC2A4 promoter fused to

and glucose infusion rate increased by 40% during hyper

CAT based on description

insulinemic euglycemic clamp.

(181)

in (175)
The authors cited a paper

Not done but cited

Compared to the control mice, transgenic mice have lower

that described a 2.4-kb of 5

previous publications(175)

blood glucose, higher lactate and β-hydroxybutyrate

flanking DNA of human

during both fasting and fed states, and improved glucose

SLC2A4 promoter fused to

transport in the soleus muscle when fed a high-fat and

CAT based on description

high-sugar diet.

in (175)
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(182)

In conclusion, adipose tissue specific GLUT4 overexpression in mice can cause increase
in body weight and adipose tissue weights (183, 184). The adipose tissue specific GLUT4
transgenic mice also have higher glucose disposal rate, maybe caused by increased basal and
insulin stimulated glucose transport rate. It is interesting to find out that the elevated expression
of GLUT4 in the adipose tissue only can increase glucose transport rate and adipose tissue
weight, which is associated with the significant increase in body weight, suggesting the
importance of GLUT4 expression in adipose tissue.
Overall, a variety of methods have been used to study GLUT4 system and insulin action
in different target tissues or cells. Results of glucose tolerance are different between mice with
whole body and tissue specific GLUT4 knockout. Although the explanation for this difference
is not clear, differences in genetic background and in developmental stages where GLUT4 is
deleted have been proposed. Moreover, whether the loss of GLUT4 in a specific tissue (muscle
or fat) or the expression of GLUT4 in other tissues without gene deletion plays a role in this
difference is worth to be investigated. More importantly, the hyperglycemia in these double
knockout mice develops in the fasting state, rather than fed state (169). This phenomenon
appears to indicate that GLUT4 plays an important role in the control of glucose homeostasis
during fasting, a state that insulin level is low.
On the other hand, the GLUT4 knockdown studies used the shRNAs method and have
been done in cell lines to reduce GLUT4 expression. This may be helpful for us to understand
the GLUT4 functions and the underlying mechanisms in particular cells. The GLUT4
overexpression in transgenic mice at whole-body level reduces blood glucose in both fasting
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Table 1-9: Tissue specific transgenic studies of GLUT4.
Tissue

Techniques

Confirmations

Results

References

Adipose

A 6.3-kb genomic DNA

GLUT4 protein

Compared to the control mice, transgenic

(183)

tissue

fragment of human SLC2A4

overexpression in both

mice have lower blood glucose in the

specific

gene under the control of a

brown and white adipose

fasting, insulin level in the fed state,

overexpress

5.4-kb’ DNA fragment of

tissue via Western blot.

higher body weight and body fat at 18 to

ion.

mouse ap2 promoter.

21weeks of age, and higher basal and

Gateway cloning.

insulin-stimulated glucose transport rates
in epididymal, parametrial, and
subcutaneous adipocytes.

Adipose

Same as in (183)

Not done but cited

Compared to the control mice, transgenic

tissue

previous publications

mice have higher body weight, parametrial

specific

(183).

fat pad weight, parametrial adipocyte size

overexpress

and body lipid, and glucose transport in

ion

both fasting and fed states; lower plasma

(184)

insulin level and glucose level after
glucose challenge;
Adipose

Same as in (183)

Not done but cited

Compared to the control mice, transgenic

tissue

previous publications

mice have higher glucose disposal in a

specific

(183).

glucose tolerance test, and palmitic acid-

overexpress

hydroxy stearic acid levels in serum, white

ion

and brown adipose tissue.

Adipose

Same as in (183)

GLUT4 protein

Compared to those fed a low-fat diet,

tissue

overexpression in both

transgenic mice fed a high-fat diet have

specific

brown and white adipose

stable expression of GLUT4, and higher

overexpress

tissue via Western blot.

glucose disposal rate, no increase of body

ion

Adipose

(185)

(186)

fat.

Same as in (183)

GLUT4 protein

Compared to the control mice, transgenic

tissue

overexpression in both

mice have higher gonadal adipose weight,

specific

brown and white adipose

basal and maximum insulin stimulated

overexpress

tissue via Western blot.

glucose transport in isolated adipocytes,

ion

glucose transport rate, triglyceride
synthesis and CO2 production.
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(187)

Table 1-9 Continued
Tissue

Techniques

Hindlimb

A 4.5-kb DNA

Confirmations

Results

References

GLUT4 mRNA

Compared to the control mice,

(171)

muscle

fragment of the mouse

overexpression in

transgenic mice have higher basal

overexpression

Slc4a2 gene under the

hindlimb muscle,

and insulin-stimulated glucose

control of a 3-kb

fat, heart, kidney,

uptake and turnover, glycogen

fragment of the mouse

brain, liver and

content in skeleton muscle, higher

myosin light chain lf

heart via Northern

insulin sensitivity, and higher free

gene promoter

blot

fatty acid and ketone levels in both

GLUT4 protein

fasting and fed state, and lower

overexpression in

fasting glucose level.

hindlimb muscle
and gastrocnemius
via Western blot.
Cell
over expression

Human SLC2A4

GLUT4 protein

Rat adipose cell transfected with

cDNA driven by the

overexpression in

GLUT4-HA had significantly

cytomegalovirus

rat adipose cell

higher antibody bonding rate under

promoter in pCIS2

via

insulin stimulation.

vector.

immunofluorescen
ce
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(188)

and fed states and increased glucose uptake, glycolysis and glycogen level (48). Compared to
the control mice, overexpression of GLUT4 in adipose tissue in mice cause lowered blood
glucose in the fasting state, and increase in body weight and adipose tissue weight (54). The
levels of GLUT4 in adipose tissue and the skeleton muscle affect the rate of whole-body
glucose disposal, may be caused by the increased basal and insulin stimulated glucose transport
rate. This lowered blood glucose level in the transgenic mice also indicates that GLUT4
probably plays a role in the basal glucose uptake.
It is safe to say that more research works are anticipated in the future to precisely define
the role of GLUT4 in the control of glucose homeostasis at whole body and tissue levels. In so
doing, we develop effective ways to prevent and treat T2DM.
5. Conclusion
VA, as a fat-soluble micronutrient, is involved in immune function, vision, reproduction,
and cell differentiation and proliferation. Most of the physiological functions of VA are exerted
through the action of RA. VA and insulin play a key role in the regulation of fuel metabolism.
They work together to regulate metabolism in vivo and in vitro.
The mass of skeletal muscle accounts for almost half of the body mass, and the regulation
of skeletal muscle glucose metabolism will significantly affect the body's glucose homeostasis.
Insulin stimulates glucose uptake and utilization in skeletal muscle. GLUT4 is important for
this in the skeletal muscle. In skeletal muscle, exercise also helps to increase insulin sensitivity
and stimulate SLC2A4 gene transcription. In addition, the type of muscle fibers can also affect
GLUT4 levels.
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So far, various methods from gene knockout to immunohistochemistry have been used to
study the mechanisms of Slc2a4 mRNA and GLUT4 expressions, and its translocation in
different cells. Every technique has its pros and cons. Based on the studies summarized here,
anti-GLUT4 antibodies from a variety of sources have been used to study GLUT4 expression
and translocation. The conclusions of these studies are based on the experimental results
derived from the use of those antibodies. A positive control derived from a cell or tissue with
unique overexpression or silencing of GLUT4 is critical to confirm the antibody’s specificity
to pick up a right signaling in the study system. This is especially true when Western blot is
used to detect GLUT4 protein expression. It appears that some of the studies did not include
control groups like this. Another challenge facing biochemical study of GLUT4 translocation
in the muscle may be sample preparations. This probably explains why fusion proteins and
stable cell lines are developed to enhance signals and specificities for detection. Confirmation
of the antibody specificity in a particular system probably should be done first.
As glucose homeostasis is a complicate process involved in many players. It is anticipated
to see that many proteins play a role in the regulation of GLUT4 system. In addition, other
GLUTs are also expressed in the same area. How GLUT4 works with other GLUTs to regulate
metabolism also deserves to be investigated. Overall, further understanding of VA signaling
system and GLUT4 system will be very helpful for us to combat the development of T2DM.
Here, to understand the effect of VA on its glucose metabolism, we hypothesized that VA
status affects glucose and FA metabolism, and regulates obesity and T2DM development in
ZDF rats, and an interaction of RA and insulin in the regulation of GLUT4 expression in L6
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cells. Therefore, we have conduct research in the following areas. (1) We have studied the
effect of VA status on the development of T2DM in ZDF rats using ZL rats as the normal
controls. Controlling VA intake and its metabolism may affect the occurrence of obesity and
T2DM in ZDF rats. (2) We have also studied the effects of insulin and RA on the expression
of GLUT4 in L6 skeletal muscle cells. We have successfully constructed a recombinant
adenovirus overexpressing GLUT4 protein and use it to compare the GLUT4 antibodies from
different commercial sources. The validated antibodies have been used to determine the
GLUT4 expression levels in L6 cells treated with or without insulin in the presence or absence
of RA. The results are shown in this dissertation.
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Chapter Two
The Effects of Vitamin A Status on the Development of Type 2 Diabetes in
Zucker Diabetic Fatty Rats
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Abstract
Previous studies in our laboratory have shown that VA status regulates glucose and lipid
metabolism in male Zucker fatty rats. Obesity development is attenuated in ZF rats fed a VAD
diet. Here, we studied the effects of VA status on the development of obesity and T2DM in
ZDF rats. ZL and ZDF rats were fed diets with different VA statuses in the presence or absence
of BF or HF content for 8 weeks. The morphometrics, serum biochemical markers, expression
levels of genes and proteins in the liver, and hepatic retinol content were determined. VA
statuses affect body mass (BM) gain in ZL and ZDF rats fed a BF or a HF diet. VAS-BF/HF
ZDF rats from 6w had respectively higher PBG levels than VAD/VAM-BF/HF ZDF rats. There
was no significant difference in PBG levels of different diets in ZL rats. The OGTT AUC
values of VAS-BF/HF ZL/ZDF rats were respectively higher than that of VAD/VAM-BF/HF
ZL/ZDF rats. In ZDF rats, we observed lower weight levels of liver and WAT to BM ratio,
plasma glucose, TG, cholesterol, insulin, and leptin of VAD diets than those of VAS in same
intake of fat content and compared with ZL rats. The hepatic Gck mRNA and its protein levels
in VAD-BF ZL rats were lower than those in VAS-BF ZL rats. The hepatic levels of Fas, and
Acl mRNA and FAS, and ACL proteins in VAM/VAS-HF ZF rats were higher than those in
VAM/VAS-HF ZL rats. The hepatic retinol content of VAD-BF/HF ZL/ZDF rats was lower
than that of VAM-BF/HF ZL/ZDF rats, which was lower than that of VAS-BF/HF ZL/ZDF
rats. The expression levels of mRNAs and proteins in the fatty acid biosynthesis pathways were
reduced in VAD-HF ZDF rats. The effects of VA on fatty acid biosynthesis in ZDF rats were
masked in a HF diet setting. These data showed that reduced VA intake prevents obesity and
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T2DM in ZDF rats.
1. Introduction
The high prevalence of obesity indicates that patients with metabolic diseases such as
T2DM will increase in the future (189). Diabetes has become a public health problem (36).
Food intake, physical activity, genetics, environment, disease, and drug interactions are factors
that lead to the development of obesity and diabetes (190). Abnormal glucose and lipid
metabolisms are usually associated with the development of obesity and T2DM (191).
Although there is a clear link between overconsumption of nutrients and the development of
obesity and T2DM, the role of individual micronutrients has not yet been clarified.
As a micronutrient, VA (retinol) plays a role in many physiological processes. Retinyl
palmitate and RA have been used as molecules with VA activity to determine the effects of
VA on T2DM in animal models. RA-treated female mice have reduced body weight, improved
intraperitoneal glucose and insulin tolerance test results, and reduced plasma retinol and RBP4
levels (192). Female rats fed a HF diet for 6 weeks developed obesity, hyperglycemia, and
insulin resistance, and completely corrected hyperglycemia and hyperinsulinemia under fasting
conditions by taking VA (12.8μg/kg/day) for 2 weeks (193). RA (10 mg/kg/day) treatment for
2 weeks reduced blood glucose levels in 9-week-old male ZDF rats (194). On the other hand,
in male albino rats fed with excessive retinyl palmitate for 2 days, liver total lipids (TG,
cholesterol), glycogen and VA contents increased (195). It appears that an excessive intake of
VA contributes to the development of fatty liver in rats (195). In the same system, rats fed
excessive amounts of VA had impaired glucose tolerance (196).
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ZDF rats have been used as a common model for the study of T2DM (197). ZDF rats
develop insulin resistance, T2DM, hyperlipidemia, moderate hypertension, obesity and
progressive renal injury (198). Previous studies in our laboratory have shown that VA plays a
role in regulating glucose and lipid metabolisms in Zucker rats (199, 200). Feeding a VAD diet
can attenuate the development of obesity in ZF rats (199). The intake of a HF diet has been
shown to cause the development of metabolic diseases such as obesity and insulin resistance
in animal models (201). However, whether the VA status plays a role in the development of
diabetes in ZDF rats fed a BF or HF diet remains to be investigated.
We hypothesized that VA status affects glucose and FA metabolisms and regulates obesity
and T2DM development in ZDF rats. In the present study, ZL and ZDF rats were fed a diet
with different VA statuses in the BF or HF condition for 8 weeks
2. Materials and Methods
2.1 Reagents
Methanol, hexane, KOH, Dextrose (D-Glucose CAS 50997), acetic acid, and ammonium
acetate were from Fisher Scientific (Waltham, MA). Retinol and retinyl acetate were from
Sigma-Aldrich Corp. (St. Louis, MO).
McKesson TURE METRIX Blood Glucose Meter and McKesson TURE METRIX test
strips (McKesson Medical-Surgical Inc) were used to measure the whole blood glucose level.
Human insulin used in the insulin tolerance test (IGT) was from Novolin® R (100 units/ml, U100, NDC 0169183302). BD Vacutainer tubes, K3 EDTA (K3E) coated vacuum blood
collection tubes, were from BD (Franklin Lakes, NJ). The insulin (FIN, Cat. # SRI-13K) and
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glucagon (Cat. # GL-32K) RIA kits were purchased from Millipore Corporation (Billerica,
MA). Agarose was from VWR international (Radnor, PA). Colorimetric kits for plasma
glucose, TG and total cholesterol levels were purchased from Stanbio Laboratory (Boerne, TX).
Rat leptin ELISA kit was purchased from RayBiotech (Norcross, GA). DNA-free and cDNA
synthesis kits, and 2 x SYBR Green real-time PCR Master Mix were from Life Technologies
(Grand Island, NY). Pyrogallol was obtained from Chemsavers Inc. (Bluefield, VA).
The bicinchoninic acid (BCA) protein assay kit was purchased from Pierce Biotechnology,
Inc (Rockford, IL) to test the protein concentration. Immobilon-PSQ PVDF membrane was
purchased from EMD Millipore Corp (Billerica, MA). Non-fat dry milk of Food Club was
purchased from a grocery store and was used to block membrane and to dissolve the first
antibodies (ACC, ACL, FAS, β-Actin, PEPCK, GCK, IRβ) and second antibody. Bovine serum
albumin (BSA) protease-free powder from Fisher BioReagents™ also was used to prepare the
antibodies solution.
For Western blot, antibodies (shown in Table 2-1) to total acetyl-CoA carboxylase (ACC,
Cat #3676), fatty acid synthase (FAS, Cat #3180 s), ATP citrate lyase (ACL, Cat #4332 s),
glycogen synthase (15B1, GS, Cat #3886), phospho-glycogen synthase (Ser641, P-GS, Cat
#3891S), glycogen synthase kinase-3 beta (D5C5Z, GSK-3β, Cat#12456), 1-acylglycerol-3phosphate-O-acyltransferase 2 enzyme (AGPAT2, Cat #14937S), Regucalcin/SMP30 (RGN,
Cat #48864S), β-actin (Cat #4970 s) and goat anti-rabbit IgG conjugated to horseradish
peroxidase (#7074) secondary antibody were from Cell Signaling Technology (Danvers, MA).
Antibodies to the cytosolic form of phosphoenolpyruvate carboxykinase (PEPCK-C,
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#10004943) and glucokinase (GCK, sc-7908) were from Cayman Chemical (Ann Arbor, MI)
and Santa Cruz Biotechnology (Dallas, TX), respectively. Insulin receptor β subunit (IRβ
#610109) was from BD Transduction Laboratories. ECL Western blotting substrate was
purchased from Pierce Biotechnology, Inc (Rockford, IL), which was used to visualize the
recognized proteins.
2.2 Animals
To establish a breeding colony of Zucker rats, male and female heterozygous Zucker rats
(Strain code, 380fa/+) were obtained from Charles River (Wilmington, MA). They were paired
as one male to one or two female(s) per cage and fed a Teklad rodent chow (#8604, Envigo).
Breeding pairs were housed in the animal facility in the Department of Nutrition at University
of Tennessee, Knoxville on a 12-hour light-dark cycle under constant temperature and humidity.
Male ZL (fa/+ or +/+) and ZDF (fa/fa) rats at 21 days of age were weaned and used in the
dietary study as indicated below. All procedures were approved by the Institutional Animal
Care and Use Committee at the University of Tennessee at Knoxville (Protocol #1256, #2647).
2.3 Rat Genotyping
Genotypes of ZL (Fa/+ and +/+) and ZDF (fa/fa) rats were determined using a PCR based
procedure as indicated in (47). Forward 5’-CGTATGGAAGTCACAGA-3’ and reverse
5’GAATTCTCTAAATATTTCAGC-3’ primers were designed to amplify a 101bp of fa allele
in the genomic DNA fragment flanking the rat Lepr mutation. The reverse primer was designed
to anneal close to the mutation site and introduce a single base substitution (C to G) in the
second base at the 3 'end of the primer to create a Pvu II restriction site in the wild-type allele
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Table 2-1: Antibody sources and operation methods
Catalog

Dilution

No.

ratio

Total acetyl CoA carboxylase (ACC)

#3676

1: 1000

Cell Signaling Technology

Fatty acid synthase (FAS)

#3180S

1: 1000

Cell Signaling Technology

Glycogen Synthase (15B1, GS)

#3886

1: 1000

Cell Signaling Technology

Phospho-Glycogen Synthase (Ser641, P-GS)

#3891S

1: 1000

Cell Signaling Technology

#12456

1: 1000

Cell Signaling Technology

#4332S

1: 1000

Cell Signaling Technology

#14937S

1: 1000

Cell Signaling Technology

Regucalcin/SMP30 (RGN)

#48864S

1: 1000

Cell Signaling Technology

Glucokinase (GcK)

#sc-7908

1: 500

Phosphoenolpyruvate carboxykinase (PEPCK-C)

#10004943

1: 1000

Cayman Chemical

Insulin receptor β subunit (IRβ)

#610109

1: 1000

BD Biosciences

β-actin

#4970 s

1: 1000

Anti-rabbit IgG, HRP-linked Antibody

#7074

1: 1000

Protein name

Glycogen synthase kinase-3 beta (D5C5Z,
GSK-3β)
ATP citrate lyase (ACL)
1-acylglycerol-3-phosphate-O-acyltransferase
2 enzyme (AGPAT2)

Manufacture

Santa Cruz Biotechnology
Inc

Cell Signaling Technology

Note: Antibodies are diluted in TBST (10 mM Tris, 150 mM NaCl, 0.1% Tween 20, pH 7.5) containing 5% bovine
serum albumin (BSA) or 5% non-fat milk. All antibodies were used according to the manufacturer’s instructions.
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and no restriction site in the mutant allele. To obtain tissue genomic DNA for analysis, ear
samples of rats after 14 days old were collected though ear punching. Seventy-five ul of
alkaline lysis buffer (25 mM NaOH/0.2 mM EDTA) was added to each tissue sample, and then
the mixture was incubated at 95 ℃ for 30 mins. After that, 75 µl of 40 mM Tris HCl buffer
was added. Then, the mixture was vortexed and spun in microfuge at 20,000 x g for 5 minutes
to obtain the tissue lysate, which contains the genomic DNA as the template for the PCR
reaction.
Each PCR reaction with a 25 µl reaction volume contained the following, 2.5 µl tissue
lysate, 2.5 µl 10 x PCR buffer, 2.5 µl 25mM MgCl2, 1 µl 100mM dNTP, 0.5 µl 5U/µl Taq
DNA polymerase, 1µl 10µM forward/reverse primer and 14 µl H2O. PCR amplification started
at 95 ℃ for 5 minutes, which was followed by 40 cycles of 95 ℃ for 30 seconds, 60 ℃ for 30
seconds, and 72 ℃ for 30 seconds. Twenty µl of the PCR product were digested with 2 units
of Pvu II (New England Biolabs) in a 28 ul volume for 1 hour at 37 ℃. After digestion, 20 µl
of the digested product were mixed with 5µl loading buffer (60% sucrose) and were loaded
onto a 4% agarose gel and electrophoresed in 0.5 x Tris-borate-EDTA (TBE) solution. The
agarose gel and TBE buffer contained 10 mg/ml ethidium bromide. As shown in a
representative gel in Figure 2-1, the wildtype genotype (+/+) shows the presence of an 80 bp
band, whereas the mutant genotype (fa/fa) shows the presence of a 101 bp band. The
heterozygotes (fa/+) genotype shows the presence of both bands (Figure 2-1).
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2.4 Diets and Experimental Groups
Male ZL (fa/+ or +/+) and ZDF (fa/fa) rats at weaning (3 weeks of age) were divided into
6 dietary groups with different VA statuses and dietary fat contents as shown in Table 2-2.
They were VA deficient with BF (VAD-BF, 0 mg retinyl palmitate/kg diet and 22.5% energy
from fat), VA marginal with BF (VAM-BF, 0.35 mg retinyl palmitate/kg diet), VA sufficient
with BF (VAS-BF, 4.0 mg retinyl palmitate/kg diet), VAD with HF (VAD-HF, 60% energy
from fat), VAM with HF (VAM-HF) and VAS with HF (VAS-HF) diets. The BF and HF diets
with different VA statuses were formulated and purchased from Envigo (#TD. 190036-190041).
The BF diets contained around 19.7% and 57.9% of energy (3.8 kcal/g) from protein and
carbohydrate, respectively. The HF diets contained around 18.5% and 21.4% of energy (5.1
kcal/g) from protein and carbohydrate, respectively. At least 5 rats after weaning in each of these
6 groups received their respective diets for 8 weeks as shown in Figure 2-2. During the feeding
period, rats were housed at 1 to 3 per cage depending on the number and genotypes of rats
available at weaning. The body mass (BM), total food intake, and peripheral blood glucose
(PBG) were measured weekly during the same period.
2.5 Insulin Tolerance Test (ITT), Oral Glucose Tolerance Test (OGTT), and Tissue
Samples
An ITT was performed after the animals were fed their respective diets for 6.5 weeks (44
days after weaning). Rats were fasted for overnight and their tail tip whole blood glucose levels
via percutaneous punching were measured as time 0 (the baseline data). The short-acting
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Figure 2-1: A representative gel of genotyping. 1-20 are samples of rats at 14 days age, fa/+, fa, + are positive
control. The PCR products without and with Pvu II digestion of each sample were run side-by-side for comparison.
Number 1 to 20 are samples from different pups.
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Table 2-2: Protein, carbohydrate, fat. VA and caloric content of each diet used in the study

Basal fat (BF)

High fat (HF)

VA statuses
Catalog NO.

VAD
#TD.
190039

VAM
#TD.
190040

VAS
#TD.
190041

VAD
#TD.
190036

VAM
#TD.
190037

VAS
#TD.
190038

Protein (%
kcal)
Carbohydrate
(% kcal)
Fat (% kcal)

20.1

19.5

19.5

18.9

18.3

18.3

57.8

57.9

57.9

21.3

21.4

21.4

22.1

22.7

22.7

59.7

60.3

60.3

VA (mg/kg)

0

0.35

4.0

0

0.35

4.0

Calories
(Kcal/g)

3.8

3.8

3.8

5.1

5.1

5.1

Note: BF diet (BF, 22% of Energy as fat) and HF diet (HF, 60% of Energy as fat) with different concentration of
VA, VA deficient (VAD, 0 mg retinyl palmitate/kg diet), VA marginal (VAM, 0.35 mg retinyl palmitate/kg diet),
VA sufficient (VAS, 4.0 mg retinyl palmitate/kg diet).

Figure 2-2: Experimental design. ZL/ZDF rats in different diets treated for 8 weeks.
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insulin (Novolin® R insulin human injection, U-100) was administrated to ZDF (0.25 U/kg
bm) and ZL (0.125 U/kg) rats intravenously. After the administration of insulin, tail tip whole
blood glucose levels at 5, 10, 15, 20, 30, 40, and 60 minutes were determined via percutaneous
punching.
An OGTT was performed after the animals were fed their respective diets for 7.5 weeks
(51 days after weaning). Rats were fasted overnight and whole blood glucose levels collected
from tail tip via percutaneous punching were measured as time 0 (the baseline data). Glucose
solution was administered to ZDF and ZL rats at a dose of 2 g/kg BW via gavage. After the
administration of glucose, tail tip whole blood glucose levels at 10, 20, 30, 60, and 120 minutes
were determined via percutaneous punching.
2.6 Plasma Parameter Measurements
At the end of the 8-week feeding protocol, rats were fasted for 6 hours and euthanized via
CO2 inhalation for the collection of plasma and tissue samples for further analysis.
Accumulated venous blood was collected using the K3 EDTA coated BD vacuum blood
collection tubes to block coagulation and placed on ice before further processing. Whole blood
samples were centrifuged at 2,000 x g for 30 minutes at 4ºC after they were collected. The
supernatant (plasma) was transferred to new microcentrifuge tube for storage. The liver was
collected after the accumulated venous blood was drained up. Liver weight was recorded before
frozen in liquid nitrogen. The two pads of epididymal white adipose tissue (WAT) were
removed carefully, weighed, and immediately frozen in liquid nitrogen. The plasma and tissue
samples were stored at -80ºC until being used for further analysis.
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The plasma concentrations of blood glucose, TG and total cholesterol levels were
determined using kits from Stanbio Laboratory (Boerne) following the manufacture’s manual.
The plasma insulin and glucagon levels were measured using the RIA kits according to the
manufacture’s manuals. The plasma leptin level was measured using the ELISA kit following
the manufacture’s manual.
The homeostasis model assessment for insulin resistance (HOMA-IR) was calculated with
the formula: HOMA-IR (nIU/ml × mM) = fasting blood glucose (mmol/L) × fasting insulin
(μU/mL)/22.5. 22.5 is the constant of glucose turnover when glucose is expressed in insulin
sensitivity index (S.I.) units.
2.7 RNA Extraction and Quantitative Real-time PCR
Total RNA was extracted from about 100 mg frozen rat liver sample using 1 ml of TRIzol
reagent (#98903, Life Technologies, Carlsbad, CA, USA) according to the manufacture’s
protocol. The contaminated DNA was removed using DNA-free kit (Applied Biosystems™,
Foster City, CA, USA), and 2 μg of DNA-free RNA was reverse-transcribed into
complementary DNA (cDNA) using cDNA synthesis kit (Applied Biosystems™ GeneAmp™
RNA PCR kit, Foster City, CA, USA). For the quantitative real-time PCR, oligo nucleotide
primer sequences for detecting glucokinase (Gck), Sterol regulatory element-binding protein 1
(Srebp-1c), Sterol regulatory element-binding protein 2 (Srebp2), Phosphoenolpyruvate
Carboxykinase 1 (Pck1), Fas, Acl, retinaldehyde dehydrogenase 1 (Raldh1), insulin-like
growth factor-binding protein 1 (Igfbp1), Stearoyl-CoA desaturase-1 (Scd1), CD36, Glucose
6-phosphatase (G6p) and Regucalcin/SMP30 (Rgn) are shown in Table 2-3. Each SYBR green
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based real-time PCR reaction contains, in a final volume of 14 μl, cDNA from 14 ng of reverse
transcribed total RNA, 2.33 pmol primers, and 7 μl of 2 x SYBR Green PCR Master Mix
(Applied Biosystems). Triplicate PCR reactions were carried out in 96-well plates using 7300
Real-Time PCR System. The conditions are 50ºC for 2 min, 95ºC for 10 min, followed by 40
cycles of 95ºC for 15 seconds (s) and 60ºC for 1 min. The mRNA level of the indicated gene
was normalized to that of invariable control gene, 36B4. -∆ cycle threshold (CT) values were
obtained by subtracting the CT value of 36B4 (an invariable control gene) from the CT values
of the indicated genes. It indicates the difference between the expression levels of 36B4 and
the indicated genes.
2.8 Protein Extraction and Western Blot
For protein sample preparation, approximately 100 mg of liver tissue was homogenized
in 1 ml liver lysis buffer (50 mM Hepes, 10 mM EDTA, 10% glycerol, 1% NP-40 and 1%
Triton X-100, 100 mM NaF, 1 mM sodium molybdate, 1 mM sodium β-glycerophsphate, 5
mM sodium orthovanadate, 1.9 mg / ml aprotinin, 5 μg / ml leupeptin, 1 mM benzamide, 2.5
mM PMSF, pH 8.0), using a tissue homogenizer (Tissue Master 240, OMNI International,
Kennesaw, Georgia) at 300 x g. This liver lysate was put on ice for at least 20 minutes, and
then centrifuged at 16,000 x g for 10 minutes. The supernatant (total hepatic lysate) was
transferred to a fresh microcentrifuge tube until being used. The protein concentration in the
total hepatic lysate was determined using the PIERCE BCA protein assay kit (Rockford,
Illinois). The protein in the total hepatic lysate (60 μg /well) was separated on an 8% or 10%
reducing SDS-PAGE gel, transferred to a PVDF membrane, and detected with a primary
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Table 2-3: Real-time PCR primer sequences of the indicated genes
Gene

Forward Sequence

Reverse Sequence

Gck

5'-CCTGGGCTTCACCTTCTCCTT-3'

5'-GAGGCCTTGAAGCCCTTGGT-3'

Srebp-1c

5′-GGAGCCATGGATTGCACATT-3′

5′-AGGCCAGGGAAGTCACTGTCT-3′

Srebp2

5'-CTGCAGATCCCGCAGTACAG-3'

5'-GGTGGATGAGGGAGAGAAGGT-3'

Pck1

5'-AGTCACCATCACTTCCTGGAAGA-3'

5'-GGTGCAGAATCGCGAGTTG-3'

Fas

5'-CAGGAACTGAACGGCATTACCTC-3'

5'-CATTTTCTAGGGATAACAGCAC-3'

Acl

5'-GCTGAAGACATTAAGAGACACCTGTT-3'

5'-AAATTGAATAGGCCGGAGATGA-3'

Raldh1

5'-ACTGTGTCATCTGCTCTG-3'

5'-TTACTCTGCTGGCTTCTT-3'

Igfbp1

5'-GATCACTGACCTCAAGAAATGGAA-3'

5'-GCGGCACGTAATCTCTCTAACA-3'

Scd1

5'-AAGATATCCACGACCCCAGCTA-3'

5'-TGCAGCAGGGCCATGAG-3'

CD36

5'-CGGCGATGAGAAAGCAGAA-3'

5'-CAACCAGGCCCAGGAGC-3'

G6p

5'-GACCTCAGGAACGCCTTCTATG-3'

5'-ATTGATGCCCACAGTCTCTTGA-3'

Rgn

5'-TCAAAGACTGTCTGCCGATG-3'

5'-GACTGTCGAAGTGCCACTGA-3'

name

Gck, glucokinase; Srebp-1c, Sterol regulatory element-binding protein 1; (Srebp2), Sterol regulatory elementbinding protein 2; (Pck1), Phosphoenolpyruvate Carboxykinase 1; Fas, Fatty acid synthase; Acl, ATP citrate lyase;
Raldh1, retinaldehyde dehydrogenase 1; (Igfbp1), insulin-like growth factor-binding protein 1; (Scd1), StearoylCoA desaturase-1; G6p, Glucose 6-phosphatase and Rgn, Regucalcin/SMP30
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antibody against the indicated protein. All the antibodies were used according to the protocols
provided by the manufacturers. Bound primary antibodies were visualized by
chemiluminescence (ECL Western Blotting Substrate, Thermo Scientific) using horseradish
peroxidase-conjugated goat anti-rabbit IgG diluted 1: 2,000 (# 7074, Cell Signaling
Technology). The membrane was exposed to X-ray film to observe the protein band. Image J
was used to measure the signal intensity of the protein bands. The ratio of target gene protein
band to β-actin band in the same sample was calculated and used for quantification.
2.9 Preparation of the Hepatic Sample for the Detection of Total Retinol Using Reversedphase High Performance Liquid Chromatography (HPLC)
All procedures were done in glass containers and conducted in dim light. About 50 mg
liver sample was homogenized in 2 ml of 100% ethanol and 100 μl of 1.0 g/ml KOH using an
OMNI international tissue master 240 (Kennesaw, GA) at 6,000 x rpm. The homogenate was
kept at room temperature in the dark for 60 minutes. In a fresh tube containing 1.4 ml of 100%
ethanol, 600 μl of lysate or distilled deionized water as the blank control was added. After that,
100 μl 20% pyrogallol (pyrogallol dissolve in 100% ethanol) was then added to each tube, and
the mixture was vortexed to mix for 30 seconds. The tubes were incubated at 55 °C in water
bath for 30 minutes and allowed to cool down to room temperature. After that, 4 ml of hexanes
(with BHT, 100μg/ml) and 2 ml ddH2O were added, shaken and vortexed to mix and kept at
4 °C for overnight. After the separation of layers, samples were centrifuged at 1,600 rpm for
15 minutes, and then approximately 3.5 ml of the upper hexanes phase was transferred into a
fresh tube, which 10 μl of retinyl acetate solution in 100% methanol (130 μmol/L) as internal
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standard was added. The mixture was dried under nitrogen gas stream at room temperature in
the dim light. Each dried sample was reconstituted in 100 μl of methanol and kept in brown
vials before HPLC analysis.
An Agilent 1260 chromatograph equipped with a variable wavelength detector operating
at 325 nm was used to detect retinoids. Samples were separated on a KR100-5C18 column (4.6
× 250 mm, No. E8218, Kromasil, S-44580 Bohus, Sweden). Elution solvents were (A) ddH2O
containing 0.01 M ammonium acetate (v/v) and (B) methanol at 21-23 °C column temperature
and a flow rate of 1 ml/minute. The injection volume was 20 μl. The total length of runs was
45 minutes and the gradient program was set as follows: 0 minute A: 5%, B: 95%; 10 min A:
30%, B: 70%; 20 minutes A: 20%, B: 80%; 25 minutes A: 5%, B: 95%; and 40 minutes A: 0%,
B: 100%. Based on the areas of retinyl acetate standards, a standard linear regression equation
was obtained. The areas of retinyl acetate and retinol in the HPLC elution curves were used to
obtain the content of hepatic retinol, which was presented as pmol/mg liver weight. The
calculate equation is Concentration of the unknown = Area unknown/(Area Internal Standard
in unknown x Concentration of the retinyl acetate standard)
2.10 Statistics Analysis
Statistical analyses were performed with GraphPad Prism 8.0 (GraphPad Software, Inc.,
San Diego, CA). The results of two groups were compared using the Student's t-test with 95%
confidence interval (CI), and where necessary natural log transformation was performed before
analysis. One-way ANOVA with LSD post-hoc statistical analysis was used to compare the
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means of three or more treatments. Data were presented as means ± S.E.M. The difference was
considered significant when the p-value was less than 0.05.
3. Results
3.1 The Effects of VA Status on Body Mass (BM), Food Intake, and PBG Levels in ZL
and ZDF Rats
To determine the effects of VA status on BM, food intake, and PBG levels of ZL or ZDF
rats fed a VAD, VAM or VAS diet with BF or HF content for 8 Weeks, we measured these
parameters weekly for 8 weeks. As shown in Figure 2-3, VAS-BF ZL and ZDF rats from 7
weeks had respectively higher BM than VAD/VAM-BF ZL and ZDF rats, respectively. VASHF ZL and ZDF rats from 6 weeks had respectively higher BM than VAD/VAM-HF ZL and
ZDF rats. The BM comparing to the previous week in VAD ZL rats stopped at week 6 in both
BF and HF diet groups, whereas VAS ZL rats continued to gain BM throughout the
experimental period. The BM of ZDF rats in the VAS-BF/HF diet groups started to rise
significantly in week 4 compared to those fed the VAD-BF/HF and VAM-BF-HF diet groups,
respectively. These results demonstrate the role of VA in BM gain in both ZL and ZDF rats.
ZDF rats are more sensitive to VA status than ZL rats in HF. As ZL, but not ZDF, VAM rats
fed the diets with BF are able to maintain growth (at a lowered rate) at week 7 and week 8. HF
diet seems to induce BM gain associated with VA as VAM and VAS rats have significantly
higher BM than VAD rats in both lean and fatty genotypes after 4 weeks treatment while ZL
and ZDF rats have significantly difference after 6 weeks treatment.
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Figure 2-3: Body Mass of ZL or ZDF rats fed a VAD, VAM or VAS diet with BF or HF content for 8 Weeks.
The body mass of ZL or ZDF rats fed with diet were measured once a week (VAD-BF ZL (n = 6), VAM-BF ZL
(n = 6), VAS-BF ZL (n = 5), VAD-HF ZL (n = 5), VAM-HF ZL (n = 6), VAS-HF ZL (n = 5), VAD-BF ZDF (n
= 5), VAM-BF ZDF (n = 5), VAS-BF ZDF (n = 5), VAD-HF ZDF (n = 6), VAM-HF ZDF (n = 6), and VAS-HF
ZDF (n = 5)). Data were expressed as mean ± SEM; * For VAD< VAS; # for VAD/VAM<VAS; $ for
VAD<VAM/VAS; & for VAD<VAM<VAS using one way ANOVA at the time point indicated, all p < 0.05.
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The average of food intake of ZL and ZDF rats started to decrease from 6 weeks when the
ITT and OGTT were preformed (Figure 2-4). Compared with that of the VAD-HF ZL and ZDF
rats, the food intakes of VAS-HF ZL and ZDF rats respectively increased significantly. A
problem for the food intake measurement is that it was very difficult to measure it accurately
since the rats were housed in groups with 1 to 3 per cage. Therefore, the difference in dietary
intake of rats in the early stage is not obvious.
For the PBG levels, there is no significant change in ZL rats fed diets in BF or HF contents
except for the ZL rats fed the VAS-BF diet, which is higher than those fed the VAD/VAM-BF
diet at week 8. VAS-BF ZDF rats from week 5 week had higher PBG levels than VAD/VAMBF ZDF rats (Figure 2-5C). Interestingly, as shown in Figure 2-5D, VAM/VAS-HF ZDF rats
from 4 weeks had a higher PBG levels than VAD-HF ZDF rats, which is one week earlier than
ZDF rats fed BF diet. Finally, VAS-HF ZDF rats had the highest PBG levels than VAD/VAMHF ZDF rats.
3.2 The Effects of VA Status on the Body Compositions of ZL and ZDF Rats
The ratios of the liver to BM (liver/BM) and the epididymal WAT to BM (WAT/BM)
were calculated to determine the effects of VA status on the body compositions of
VAD/VAM/VAS-BF/HF ZL and ZDF rats. As shown in Figure 2-6A, at the time of sacrifice,
the liver/BM ratio of VAD/VAM-BF ZDF rats were significantly lower than that of VAS-BF
ZDF rats. The liver/BM ratios of VAD-HF ZDF rats were lower than that of VAS-HF ZDF
group. The liver/BM ratios of VAS-BF ZDF rats were higher than that of VAS-BF ZL rats.
Also, the liver/BM ratios of VAS-BF ZDF were higher than that of VAS-HF ZDF rats. As
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Figure 2-4: Food intake of ZL or ZDF rats fed a VAD, VAM or VAS diet with BF or HF content for 8
Weeks. The average amount of diet consumed by ZL or ZDF rats fed with diet were measured once a week (VADBF ZL (n = 6), VAM-BF ZL (n = 6), VAS-BF ZL (n = 5), VAD-HF ZL (n = 5), VAM-HF ZL (n = 6), VAS-HF
ZL (n = 5), VAD-BF ZDF (n = 5), VAM-BF ZDF (n = 5), VAS-BF ZDF (n = 5), VAD-HF ZDF (n = 6), VAMHF ZDF (n = 6), and VAS-HF ZDF (n = 5)). Data were expressed as mean ± SEM; *VAD vs. VAS, # VAD <
VAM, & VAM > VAS, all p < 0.05.
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Figure 2-5: Peripheral blood glucose levels of ZL or ZDF rats fed a VAD, VAM or VAS diet with BF or HF
content for 8 Weeks. The PBG level from rat tail tips were measured once a week (VAD-BF ZL (n = 6), VAMBF ZL (n = 6), VAS-BF ZL (n = 5), VAD-HF ZL (n = 5), VAM-HF ZL (n = 6), VAS-HF ZL (n = 5), VAD-BF
ZDF (n = 5), VAM-BF ZDF (n = 5), VAS-BF ZDF (n = 5), VAD-HF ZDF (n = 6), VAM-HF ZDF (n = 6), and
VAS-HF ZDF (n = 5)).. Data were expressed as mean ± SEM; * For VAD< VAS; ^ for VAM<VAS: # for
VAD/VAM<VAS; $ for VAD<VAM/VAS, all p < 0.05.
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shown in Figure 2-6B, the WAT/BM ratios of VAD-HF ZDF rats were lower than that of VASHF groups which shown the same trend as the liver/BM ratio. There is no difference in VAMBF/HF ZL/ZDF group The HF diets can increase the WAT/BM ratio in ZDF rats as the values
of VAS-HF ZDF rats were higher than that of VAS-BF ZDF rats. The WAT/BM ratios of ZDF
rats were higher than ZL rats fed same diets. All these data indicated that VA status does affect
liver/BM ratio and WAT/BM ratio in ZDF rats.
3.3 Hepatic Retinol Content in the ZL and ZDF Rats Fed Diets with Different VA
Contents
Figure 2-7 shows that the hepatic retinol content in VAD-BF/HF ZL groups and VADHF ZDF groups were respectively lower than that in VAM-BF/HF ZL groups and VAM-HF
ZDF groups, which is respectively lower than that in VAS-BF/HF ZL groups and VAS-HF
ZDF groups. The hepatic retinol content in VAD/VAM-BF ZDF groups were significantly
lower than that in VAS-BF ZDF group. In ZL rats, the retinol contents of VAD/VAM/VASHF groups were significantly higher than that of VAD/VAM/VAS BF groups, respectively.
The hepatic retinol content of VAS-BF ZDF group was higher than that in VAS-BF ZL group.
The hepatic retinol results show that VA statuses of ZL and ZDF rats reflect their dietary VA
contents. ZL rats fed a HF diet store more VA in the liver than those fed a BF diet. ZDF rats
fed a VAS-BF diet will store more VA in the liver than ZL rats, which probably reflects the
excessive VA intake of ZDF rats.
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Figure 2-6: The ratios of liver/BM and WAT/BM were calculated and compared between VAD/VAM/VASBF/HF ZL and ZDF rats. The ratios of liver/BM and WAT/BM were calculated and compared (VAD-BF ZL (n
= 6), VAM-BF ZL (n = 6), VAS-BF ZL (n = 5), VAD-HF ZL (n = 5), VAM-HF ZL (n = 6), VAS-HF ZL (n = 5),
VAD-BF ZDF (n = 5), VAM-BF ZDF (n = 5), VAS-BF ZDF (n = 5), VAD-HF ZDF (n = 6), VAM-HF ZDF (n =
6), and VAS-HF ZDF (n = 5)). Data were represented means ± SEM of 12 independent groups. In liver/BM *
p<0.05, ** p<0.01,*** p<0.001 VAS-BF ZDF rats vs. other groups; # p<0.05, ## p<0.01 VAS-HF ZDF rats vs.
other group. In WAT/BM, * p<0.05, ** p<0.01,*** p<0.001 ZL rats vs. ZDF rats in same diet; # p<0.05, ##
p<0.01 VAS-HF ZDF rats vs. other group. Data were represented as means ± SEM.

Figure 2-7: Hepatic Retinol Content of ZL and ZDF rats fed a VAD, VAM or VAS diet with BF or HF
content. liver tissues were harvested and prepared for analysis (VAD-BF ZL (n = 6), VAM-BF ZL (n = 6),
VAS-BF ZL (n = 5), VAD-HF ZL (n = 5), VAM-HF ZL (n = 6), VAS-HF ZL (n = 5), VAD-BF ZDF (n = 6),
VAM-BF ZDF (n = 6), VAS-BF ZDF (n = 6), VAD-HF ZDF (n = 6), VAM-HF ZDF (n = 6), and VAS-HF ZDF
(n = 6)). a<b<c, a’<b’<c’, a”<b”, and a’”<b’”<c’” for comparing the groups in the same dietary fat content and
genotype using one way ANOVA; * for comparing ZL and ZDF groups fed the same diet; ** for comparing BF
with HF groups within the same genotype
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3.4 The Effects of VA Status on ITT and OGTT of ZL and ZDF Rats
After overnight fast, ITT were measured at morning around 10-11 am. In ITT, PBG levels
of VAD/VAS-BF and VAM-BF ZL rats dropped until 15 mins and 20 mins, respectively. PBG
levels of VAD-HF and VAM/VAS-HF ZL rats declined until 30 mins and 15 mins, respectively.
PBG levels of VAM-BF and VAS-BF ZDF rats dropped until 15 mins and 5 mins, respectively.
PBG levels of VAD-BF ZDF rats started to drop after 10 mins and stopped after 20 mins. PBG
levels of VAD/VAM-HF and VAS-HF ZDF rats dropped to the lowest until 15 mins and 20
mins, respectively (Figure 2-8). PBG levels of VAS-HF ZDF rats in ITT was significantly
greater than that in VAD/VAM-HF ZDF rats, indicating insulin resistance in them.
After overnight fast, OGTT were measured at morning around 10-11 am. The OGTT
results showed that PBG levels of VAS-BF ZL rats peaked at 10 minutes. VAS-BF/HF ZL rats
had significantly higher PBG levels than VAD/VAM-BF/HF ZL rats, respectively. PBG levels
of all ZDF rats peaked at 60 mins (except for VAS-BF ZDF rats at 30) before dropped (Figure
2-9). Both VAS-BF/HF ZL and ZDF groups also displayed higher blood glucose levels during
the OGTT respectively compared to VAD/VAM-BF/HF ZL and ZDF groups. In Figure 2-10,
the OGTT area under the curve (AUC) values of VAS-BF ZL rats were higher than that of
VAD/VAM-BF ZL rats. In HF diet condition, the AUC values of VAS-HF ZL rats were higher
than that of VAM-HF ZL rats, and that of VAM-HF ZL rats were higher than that of VAD-HF
ZL rats. In ZDF, the OGTT AUC values of VAS-BF/HF ZDF rats were higher than that of
VAD/VAM-BF/HF ZDF rats, respectively. The comparison of ZL and ZDF groups with the
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same diet, ZDF rats’ AUC values were significantly higher than that of ZL rats. This indicating
an impaired glucose tolerance in VAS-BF/HF ZL or ZDF rats.
3.5 The Effects of VA on Plasma Levels of Glucose, TG, Cholesterol, Insulin, Glucagon,
and Leptin in ZL and ZDF Rats
To investigate the effects of VA status on glucose and lipid metabolism, we compared the
plasma levels of glucose, TG, and cholesterol in ZL and ZDF rats fed a VAD, VAM or VAS
diet with BF or HF diet. Figure 2-11 A shows that the plasma glucose levels of
VAD/VAM/VAS-HF ZDF rats were higher than that in HF ZL rats. Compared with that of ZL
rats, the glucose levels of VAM-BF rats were significantly higher than VAD/VAS-BF. The
glucose levels of venous plasma were significantly lower in VAD-HF ZDF rats than
VAM/VAS-HF ZDF rats. These results demonstrating that VA deficiency results in a reduction
in plasma glucose level of ZL and ZDF rats.
Figure 2-11 C shows that the plasma insulin levels of VAD/VAM/VAS-BF/HF ZL rats
were significantly lower than that in ZDF rats. The plasma insulin levels of VAD/VAM-BF/HF
ZDF rats were significantly lower than that in VAS-BF/HF ZDF rats. These results indicate
that the dietary VA may directly affects plasma insulin levels in ZDF rats. Also, the genetic
predisposition to diabetes is more influential on plasma insulin levels than VA status when
comparing between VAD-BF ZL rats and VAD-BF ZDF rats.
The TG and cholesterol levels of vena cava plasma in VAD/VAM/VAS-BF ZDF rats were
higher than that in BF ZL rats (Figure 2-11 B and D). These levels in VAD/VAM/VAS-HF
ZDF rats were higher than that in HF ZL rats. These results reveal that body fat mass affects
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Figure 2-8: Peripheral glucose levels of ZL or ZDF rats fed a VAD, VAM or VAS diet with BF or HF
content after insulin tolerance test at 6.5 weeks. Data were expressed as mean ± SEM, * p<0.05. VAD-BF ZL
(n = 6), VAM-BF ZL (n = 6), VAS-BF ZL (n = 5), VAD-HF ZL (n = 5), VAM-HF ZL (n = 6), VAS-HF ZL (n =
5), VAD-BF ZDF (n = 5), VAM-BF ZDF (n = 5), VAS-BF ZDF (n = 5), VAD-HF ZDF (n = 6), VAM-HF ZDF
(n = 6), and VAS-HF ZDF (n = 5).
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Figure 2-9: Peripheral glucose levels and Glucose Area Under the Curve (AUC) after oral glucose tolerance
test of ZL or ZDF rats fed a VAD, VAM or VAS diet with BF or HF content at 7.5 weeks. Data were expressed
as mean ± SEM, (A-D) * for VAD<VAS; ^ for VAM<VAS; # for VAD/VAM<VAS; $ for VAD<VAM/VAS; ~
for VAM<VAD/VAS, p<0.05. VAD-BF ZL (n = 6), VAM-BF ZL (n = 6), VAS-BF ZL (n = 5), VAD-HF ZL (n
= 5), VAM-HF ZL (n = 6), VAS-HF ZL (n = 5), VAD-BF ZDF (n = 5), VAM-BF ZDF (n = 5), VAS-BF ZDF (n
= 5), VAD-HF ZDF (n = 6), VAM-HF ZDF (n = 6), and VAS-HF ZDF (n = 5).

Figure 2-10: Area under the curve (AUC) values of the oral glucose tolerance test in ZL and ZDF rats fed
a VAD, VAM or VAS diet with BF or HF content. a<b, a’<b’, a”<b”, and a’’’<b’’’ for comparing the groups
in the same fat content and genotype using one way ANOVA; * for comparing ZL and ZDF groups with the
same diet; ** for comparing BF with HF groups within the same genotype, p<0.05. VAD-BF ZL (n = 6), VAMBF ZL (n = 6), VAS-BF ZL (n = 5), VAD-HF ZL (n = 5), VAM-HF ZL (n = 6), VAS-HF ZL (n = 5), VAD-BF
ZDF (n = 5), VAM-BF ZDF (n = 5), VAS-BF ZDF (n = 5), VAD-HF ZDF (n = 6), VAM-HF ZDF (n = 6), and
VAS-HF ZDF (n = 5)
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the plasma TG and cholesterol levels, a normal physiological phenomenon. The plasma TG
levels of VAD-BF/HF ZL or ZDF rats were lower than VAS-BF/HF ZL or ZDF rats
respectively, which means VA deficiency results in a reduction in plasma glucose and TG
levels in ZL and ZDF rats. The plasma cholesterol levels in VAD/VAM-BF/HF ZDF rats
significantly decreased compared with that in VAS-BF/HF ZDF rats.
Figure 2-11 E shows that the leptin levels of VAD/VAM-BF/HF ZDF rats were lower
than that of VAS-BF/HF ZDF rats. The VAD/VAM-HF ZL group had lower leptin levels than
VAS-HF ZL group. The leptin levels of VAD/VAM/VAS-BF/HF ZL rats were significantly
lower than that of VAD/VAM/VAS-BF/HF ZDF rats respectively, probably due to the
reduction of body fat mass. There is a significant increase of plasma leptin levels in VAS-HF
ZL rats compare with that in VAS-BF ZL rats. These results indicate that VA status may affect
the plasma leptin levels via the control of adiposity in rats, and the dietary VA does not affect
the plasma leptin level in ZL rats with a BF diet based on this ELISA assay. The glucagon
levels of vena cava plasma in VAS-HF ZDF rats were higher than that in VAS-HF ZL rats and
lower than that in VAS-BF ZDF rats (Figure 2-11 F).
VAS-BF/HF ZDF rats had respectively higher HOMA-IR values than that of VAD/VAMBF/HF ZDF rats. The HOMA values of VAM/VAS-HF ZDF rats were higher than that of
VAM/VAS-BF ZDF rats. These results indicate that ZDF rats use more insulin than ZL rats to
keep blood glucose in balance, indicating that VAS-BF/HF ZDF rats are the most insulin
resistant compared with VAS-BF/HF ZL rats and VAD/VAM-BF/HF ZDF rats, respectively.
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Figure 2-11: The plasma levels of glucose, TG, insulin, cholesterol, leptin, glucagon and HOMA-IR in ZL
and ZDF rats fed a VAD, VAM or VAS diet with BF or HF content. (A-E, G) a<b, a’<b’, a”<b”, and
a’’’<b’’’ for comparing the groups in the same fat content and genotype using one way ANOVA; * for
comparing ZL and ZDF groups with the same diet; ** for comparing BF with HF groups within the same
genotype, P<0.05. (F) a for comparing the BF and HF conditions with the same rat genotype and VA status; b
for comparing the ZL and ZDF rats in the same VA status and dietary fat content. VAD-BF ZL (n = 6), VAMBF ZL (n = 6), VAS-BF ZL (n = 5), VAD-HF ZL (n = 5), VAM-HF ZL (n = 6), VAS-HF ZL (n = 5), VAD-BF
ZDF (n = 6), VAM-BF ZDF (n = 6), VAS-BF ZDF (n = 6), VAD-HF ZDF (n = 6), VAM-HF ZDF (n = 6), and
VAS-HF ZDF (n = 6)
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3.6 The Effects of VA on the mRNA Expression Levels of Hepatic Genes for Glucose
and Lipid Metabolism in ZL and ZDF Rats
To confirm whether the VA status in the liver contributes to the regulation of the hepatic
glucose and fatty acid metabolism, we compared the hepatic mRNA levels of Gck (glycolysis),
Srebp-1c (fatty acid synthesis), Srebp2 (cholesterol synthesis), Pck1(gluconeogenesis), Fas
(fatty acid synthesis), Acl (fatty acid synthesis), Raldh1 (retinal dehydrogenase 1),
Igfbp1(insulin-like growth factor binding protein), Scd1 (lipogenesis), CD36 (facilitates fatty
acid uptake), G6p (gluconeogenesis) and Rgn (cellular growth and apoptosis) in ZL and ZDF
rats fed a VAD, VAM or VAS diet with BF or HF content. The Ct numbers of these genes are
normalized to the Ct number of 36B4 (a control gene) as -ΔCt in the same sample. Based on
the values of -ΔCt, we found that these genes are expressed at a meaningful level in rat liver.
Figure 2-12A shows that in both BF and HF conditions, the hepatic mRNA expression
levels of Gck in VAD/VAM ZL groups were lower than that in VAS group. In ZL rats, the Gck
mRNA levels in VAS-HF group were increased significantly compared with that in VAS-BF
group. Also, the Gck mRNA levels in VAD-BF ZDF rats were significantly higher than that in
VAD-BF ZL rats. These results demonstrate that VA is needed to sustain the hepatic expression
of Gck in ZL rats, and especially in HF diet condition. VA status regulates the hepatic
expression of Gck.
Figure 2-12B shows that the mRNA levels of Srebp-1c of ZL rats in VAD-BF group were
lower than in VAM/VAS-BF and VAD-HF groups. In contrast, Srebp2 mRNA levels of VADBF ZL rats were higher than that of VAM/VAS-BF and VAD-HF ZL rats (Figure 2-12C). The
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Srebp-1c mRNA levels in VAM-HF ZDF group were higher than that in VAM-BF ZDF group.
The Srebp2 mRNA levels of VAS-BF ZDF rats were lower than that of VAD-BF ZDF rats.
Also, VAM-HF ZDF rats have higher Srebp-1c mRNA expression levels than VAM-HF ZL
rats. In contrast, ZDF rats in all dietary groups had significantly lower Srebp2 mRNA
expression levels than ZL rats fed the same diets respectively (except VAS-HF group). This
demonstrates that VA induces Srebp-1c, and depresses Srebp2 mRNA levels in BF condition,
and does not affect Srebp-1c and Srebp2 mRNA levels in HF condition.
As shown in Figure 2-12D, the hepatic expression levels of Pck1 in VAD/VAS-HF ZL
groups were higher than that in VAM-HF group. The hepatic expression levels of Fas in ZL
rats (Figure 2-12E) showed the same pattern as Pck1. The levels Pck1 (Figure 2-12D) and
Raldh1 (Figure 2-12G) in VAM-HF ZDF group were lower than that in VAD/VAS-HF groups,
respectively. The mRNA levels of Fas (Figure 2-12E) and Acl (Figure 2-12F) in VAS-HF ZDF
group were significantly higher than that in VAD/VAM-HF group. The Pck1mRNA levels of
ZDF rats in all dietary groups were decreased compared with that of ZL rats in same dietary
groups, respectively. In contrast, the Fas mRNA levels in both BF and HF of ZDF rats were
significantly increased compared with that of the ZL rats in same dietary groups (except for
the VAD-HF group). The Acl mRNA levels of VAM-BF and VAD/VAM/VAS-HF ZDF
groups were significantly increased compared with that of ZL rats in the same dietary groups,
respectively.
The Raldh1 mRNA levels of VAM-HF ZDF rats were decreased compared with that of
VAM-HF ZL rats. The Pck1 and Fas mRNA levels of VAM-HF group were significantly
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higher than that of VAM-BF group in ZL rats. In contrast, Raldh1 and Acl mRNA levels of
VAM-HF group were lower than that of VAM-BF group in ZL rats. Also, the Pck1 and Acl
mRNA levels of VAS-BF group were significantly lower than that of VAS-HF group in ZDF
rats. Thus, VA status affects the expression levels of Pck1, Fas, Acl, and Raldh1 at BF or HF
conditions in ZL and ZDF rats. The expression levels of Pck1, Fas, Acl, and Raldh1 in VAMHF group are lower than the VAD/VAS-HF groups, showing a possible bidirectional regulation
of these genes in response to VA status in HF conditions.
The hepatic of Igfbp1 mRNA levels in VAD-BF/HF groups of ZL rats and VAD-HF
groups of ZDF rats were significantly higher than that of other groups (Figure 2-12H). The
Igfbp1 mRNA levels in both BF and HF of ZDF rats were significantly reduced compared with
that of ZL rats in the same dietary groups (except VAM-BF group), respectively. In both ZL
and ZDF rats, the Igfbp1 mRNA levels in VAM-HF groups were significantly decreased
compared with that in the BF groups. VAD diets dramatically induced the expression levels of
Igfbp1 mRNA, showing that VA deficiency induces the hepatic Igfbp1 expression in both ZL
and ZDF rats.
The hepatic expression levels of Scd1, CD36, G6p and Rgn were elevated in VAS-HF
ZDF group compared with that of VAD/VAM-HF ZDF groups (Figure 2-12I-L). In ZL rats,
CD36 mRNA levels of VAD-BF group were higher compared with that of VAM/VAS-BF
groups (Figure 2-12J). In contrast, the G6p and Rgn mRNA levels of VAD-BF ZL group were
lower compared with that of VAM/VAS-BF ZL groups, respectively (Figure 2-12K and L).
Also, the Scd1mRNA levels in VAD-BF ZL group were lower than that in VAM-BF ZL group,
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which were lower than that in VAS-BF ZL group. The Rgn mRNA levels in VAD/VAM-HF
ZL groups were also decreased compared with that in VAS-HF ZL group. In ZDF rats, the
mRNA levels of Scd1, CD36 and Rgn in VAD/VAM-HF group were lower than that in VASHF group. The G6p mRNA levels in VAM-HF ZDF group were lower than that in VAD-HF
ZDF group, which were lower than that in VAS-HF ZDF group.
The Scd1 mRNA levels of VAD/VAM-BF groups and VAM/VAS-HF groups in ZDF rats
were significantly higher than that of same diets in ZL rats. The CD36 m RNA levels of VAMBF group and VAS-HF group in ZDF rats were higher than that of same diets in ZL rats,
respectively. The G6p mRNA levels of VAS-BF/HF groups and VAM-HF group in ZDF rats
were lower than that of same diets in ZL rats. The Rgn mRNA levels of all dietary groups in
ZDF rats were respectively lower than that in ZL rats.
The Scd1 mRNA levels of VAS-BF group were higher than that of VAS-HF group in ZL
rats. The Rgn mRNA levels of VAS-HF ZL group were higher than VAS-BF ZL group. The
Scd1, G6p and Rgn mRNA levels of VAS-HF ZDF group were higher in than that of VAS-BF
ZDF group. The CD36 mRNA levels of VAM-HF were lower than that of VAM-BF in ZDF
rats. These results show that VA deficiency contributes to the reduced levels of hepatic Scd1,
G6p and Rgn and induced levels of CD36 in ZL rats fed a BF diet. Also, VA deficiency reduces
Rgn expression in ZL rats fed a HF diet. Enough VA significantly supports the hepatic
expression of Scd1, and G6p in ZDF rats fed a HF diet. Adequate VA intake may suppress
CD36 expression in ZDF rats fed a HF diet. Enough VA maintains the hepatic Rgn mRNA
levels in ZL and ZDF rats fed a BF or HF diet.
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Figure 2-12: The mRNA levels of Gck, Srebp-1c, Srebp2, Pck1, Fas, Acl, Raldh1, Igfbp1, Scd1, CD36, G6p
and Rgn in ZL and ZDF rats fed a VAD, VAM or VAS diet with BF or HF content. Liver tissue samples
were collected at the end of the treatment (VAD-BF ZL (n = 6), VAM-BF ZL (n = 6), VAS-BF ZL (n = 5), VADHF ZL (n = 5), VAM-HF ZL (n = 5), VAS-HF ZL (n = 5), VAD-BF ZDF (n = 6), VAM-BF ZDF (n = 5), VASBF ZDF (n = 6), VAD-HF ZDF (n = 5), VAM-HF ZDF (n = 5), and VAS-HF ZDF (n = 5)). Total RNAs were
extracted and subjected to real-time PCR analysis. Results were presented as means ± SEM of the -∆CT. (A, B,
F, I, K, L) a<b<c, a’<b’, a”<b”, and a’’’<b’’’ for comparing the groups in the same fat content and genotype
using one way ANOVA. (C, D, G, H) a>b, a’>b’, and a” >b” in the same genotype and dietary fat content groups
using one way ANOVA. (E, J) a>b and a’<b’ in the same genotype and dietary fat content groups using one way
ANOVA. All shown * for comparing ZL and ZDF groups with the same diet; ** for comparing BF with HF
groups within the same genotype, P<0.05.
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Figure 2-12 Continued
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3.7 The Effects of VA on the Protein Levels of Hepatic Genes for Glucose and Lipid
Metabolism in ZL and ZDF Rats
To investigate the effect of VA status on the hepatic proteins for the fatty acid synthesis,
glucose metabolism, glycogen synthesis and insulin signaling pathways in ZL and ZDF rats, we
analyzed the hepatic expression levels ACC, FAS, ACL, IRβ, PEPCK, GCK, GS, P-GS, GSK-3β,
RGN, and AGPAT2 proteins using immune-blot.
Figure 2-13A shows that the hepatic ACL levels in VAD-BF ZL group were lower than that
in VAM-BF ZL group, which is lower than that in VAS-BF ZL group. The IRβ, GCK, GS, GSK3β, and RGN levels in VAD/VAM-BF ZL groups were respectively lower than that in VAS-BF
ZL group. The PEPCK levels in VAM-BF ZL group were lower than that in VAS-BF ZL group.
The levels of AGPAT2 in VAM-BF ZL group were higher than that in VAD-BF ZL group. The
other proteins levels were not significantly changed by the VA and dietary fat statuses. These
results demonstrate that VA status affects the expression levels of ACL, IRβ, PEPCK, GCK, GS,
GSK-3β, RGN and AGPAT2 protein in liver. In ZL rats, enough VA supports the hepatic
expression levels of ACL, IRβ, PEPCK, GCK, GS, GSK-3β and RGN in BF conditions, and
adequate VA intake could elevate hepatic proteins expression of AGPAT2 in BF conditions.
As shown in Figure 2-13B, the ACL expression levels in VAD-HF ZL group were lower than
that in VAS-HF ZL group, which were lower than that in VAM-HF ZL group. The IRβ expression
levels in VAS-HF ZL group were lower than that in VAD-HF ZL group. The GS protein
expression levels in VAS-HF ZL group were lower than that in VAD/VAM-HF ZL groups. The
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presence of VA supports the hepatic ACL expression, and sufficient VA might suppress the
expressions of IRβ and GS in ZL rats fed a HF diet.
Figure 2-13C shows that ACC and ACL levels in VAD/VAM-BF ZDF groups were
significantly lower than that of VAS-BF ZDF group. In contrast, IRβ levels in VAD/VAM-BF
ZDF groups were significantly higher than that in VAS-BF ZDF group. FAS and PEPCK levels
in VAD-BF ZDF group were significantly lower than that of VAS-BF ZDF group. RGN levels in
VAD-BF ZDF groups were lower than that in VAM/VAS-BF ZDF groups. AGPAT2 levels in
VAD-BF ZDF group were lower than that in VAM-BF ZDF group, which were lower than that in
VAS-BF ZDF group. Enough VA supports the hepatic ACC, FAS, ACL, PEPCK, RGN, and
AGPAT2 expressions, and depresses IRβ expression in ZDF rats fed a BF diet.
Figure 2-13D shows that ACC, FAS, and ACL levels in VAD/VAM-HF ZDF groups were
significantly lower than that of VAS-HF ZDF group. IRβ levels in VAM-HF ZDF group were
significantly higher than that in VAS-HF ZDF group. The GCK, RGN, and AGPAT2 levels in
VAD-HF ZDF groups were significantly lower than that in VAM/VAS-HF ZDF groups. The GS
levels were lower in VAS-HF group than that in VAD-HF ZDF group, which were lower than that
in VAM-BF ZDF group. However, p-GS levels were not significantly different among these
groups. GSK-3β levels in VAD-HF ZDF group were lower than that in VAS-HF ZDF group. These
results show that VAS status suppresses IRβ and GS levels, and supports ACC, FAS, ACL, GCK,
GSK-3β, RGN, and AGPAT2 expressions in ZDF rats fed a HF diet.
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Figure 2-13: The Protein levels of ACC, FAS, ACL, IRβ, PEPCK, GCK, GS, P-GS, GSK-3β, RGN, and
AGPAT2 in ZL and ZDF rats fed a VAD, VAM or VAS diet with BF or HF content. Liver samples were
collected at the end of the treatment. Proteins (60 μg/well) in whole cell lysates were isolated and subjected to
western blot analysis. The ImageJ Software was used to determine the densitometry of a protein band. Results
were presented as means ± SEM of the ratio of the measured protein to β-actin. (A) a<b, a’<b’, a”<b”, a’’’<b’’’,
c<d, c’<d’, c”<d”, and c’’’<d’’’ for comparing the groups in the same fat content and genotype using one way
ANOVA, P<0.05. (B) a<b<c, a’<b’, and a”<b” for comparing the groups in the same fat content and genotype
using one way ANOVA, P<0.05. (C, D) a<b, a’<b’, and a”<b”, a’’’<b’’’, c<d, c’<d’<e’, c”<d”, c’’’<d’’’<e’’’,
and e<f for comparing the groups in the same fat content and genotype using one way ANOVA, P<0.05.
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Figure 2-13 Continued
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Figure 2-13 Continued
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Figure 2-13 Continued
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4. Discussion
To understand the development and progression of metabolic diseases, the role of VA in
obesity diabetes and metabolic abnormalities is of great importance. We studied the effects of the
intake of VA associated with obesity and diabetes. ZDF rats which bear a loss-of-function leptin
receptor gene, have been extensively used to study the pathogenesis of T2DM, obesity, leptin
signaling, and the interactions among the three (202). This animal model develops obese and
insulin resistance with dyslipidemia due to hyperphagia (202). Here, we investigated the effects of
dietary VA status on the glucose and lipid metabolism of ZL and ZDF rats in BF and HF conditions.
The nutritional, morphometrics, serum biochemical markers, liver gene and protein expressions of
glucose and fatty acid metabolism, and hepatic retinol content were investigated.
The content of hepatic retinol meets the intake of dietary VA. There are two sources of VA
in the liver: VA stored in the hepatic stellate cells and VA in the diet. VAD rats that deplete liver
VA storage and cause VA deficiency need to obtain VA from their diet. VAS rats have sufficient
VA storage in the liver to maintain a constant plasma VA level. The contents of hepatic retinol in
ZL and ZDF rats indicate that VA intake is needed to maintain the hepatic VA status. The HF
condition appears to increase the hepatic VA content in both ZL and ZDF rats. Therefore, VAM
and VAS still had endogenous VA to regulate the expression of VA responsive genes and proteins,
whereas VAD rats have extremely low hepatic retinol content. All these results clearly demonstrate
that the current experimental setting alters the VA status in ZL and ZD rat. Therefore, ZL and ZDF
rats fed diets with different contents of VA are functional models to study the impact of VA on
glucose and lipid metabolisms.
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The BM data indicate that rats fed a VAD diet gain less BM than those fed a VAM or VAS
diet depending on the genetic setting of the rats and dietary fat content. ZDF rats fed the VAS diets
gain more weight than ZL rats fed the VAS diet in BF and HF conditions, respectively. This is due
to the hyperphagia of ZDF rats. These results are similar to what we have observed in ZL and ZF
rats fed a VAD or VAS diet with normal fat content as shown in (200, 203, 204). Also, in both ZL
and ZDF rats, HF diets promote more BM gain than BF diets. The VAM-HF ZL and ZDF rats gain
more BM than VAD-HF ZL and ZDF rats, indicating that HF diets might have lowered the needs
of VA in VAM rats. VA deficiency reduces the obesity development in ZDF rats.
The data of previous studies have shown that ZL and ZF rats reduce food intake when they
reach VA deficiency (200, 204-206). In this study, ZL or ZDF rats were fed a VAD-BH/HF, VAMBH/HF or VAS-BH/HF diet for 8 weeks. The development of VA deficiency causes a suppression
of appetite in both BF and HF content of ZL and ZDF rats. Compared with ZDF rats fed the VAD
or VAM, diets, the food intakes of VAS-BF/HF ZDF rats continuously increase. One possibility
is the inhibition of fatty acid synthesis or an increase in fatty acid oxidation in the brain (where
appetite is regulated) of VAD animals. It has been shown that alteration of fatty acid synthesis and
oxidation in the brain reduces food intake and causes weight loss in animals (207). This indicates
that VA status contributes to BM gain and food intake in ZL and ZDF rats, a process that can be
affect by dietary fat content to certain extent.
The PBG levels of VAS-BF/HF ZDF rats are respectively higher than that of VAD/VAMBF/HF ZDF rats at the same weeks, which correspond to significant BM differences due to VA
statuses (after 5 weeks of feeding of the BF and 4 weeks of feeding of HF diets). ZDF rats develop
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obesity, insulin resistance, hyperinsulinemia, hyperlipidemia, and obesity-induced diabetes (48).
Insulin from β cells regulates blood glucose and blood lipid levels (208). Glucagon promotes liver
glucose production, glycogenolysis, and ketone production in response to hypoglycemia, while
insulin promotes glucose processing, glycogenesis, and lipogenesis in response to elevated blood
glucose levels (208). Insulin resistance is a state in which cells cannot respond effectively to insulin
stimulation leading to hyperglycemia (209). With the increase of VA intake, the increase in blood
glucose concentration is consistent with the metabolic disorder in VAS-BF/HF ZDF rats.
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and OGTT assays were given after the respective diets are fed for 6 weeks and ZDF rats already
develop obesity and diabetes. The data show insulin resistance in VAS-HF ZDF rats and impaired
glucose tolerance in VAS-BF/HF ZDF rats. The accumulated venous plasma glucose levels in
VAS-HF ZDF rats were also significantly increased with the elevation of VA status (Figure 210A). These results in ZDF rats were consistent with previous observations in ZF rats (204). It
shows the important role of VA status in the regulation of plasma glucose hemostasis.
Previous research results from our lab have shown that VA deficiency leads to reduction of
plasma leptin and insulin levels in ZL and ZF rats (204-206). The plasma levels of insulin and
leptin levels in ZDF rats are also decreased with the reduction of VA status (Figure 2-10C). The
development of hyperinsulinemia precedes the development of diabetes, which is associated with
change of hepatic genes involved in glucose and lipid metabolism (200). Insulin stimulates leptin
synthesis and secretion, whereas leptin can also affect the insulin secretion and functions (210). In
addition, the TG and cholesterol levels in ZL and ZDF rats are all lowered with the reduction of
VA status, demonstrating the roles of VA in the regulation of TG and cholesterol metabolism. The
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hyperinsulinemia, hyperglycemia and hyperleptinemia in ZDF rats show the correlations of these
plasma parameters, which all can be attenuated by the reduction of VA status. The underlying
mechanisms by which VA status regulates glucose, insulin and leptin levels in obesity and diabetes
deserve to be studied further.
To explain the changes of plasma parameters, we investigated the effects of VA status on the
mRNA and protein levels of hepatic genes for glucose and lipid metabolism in ZL and ZDF rats
fed BF or HF diets with different VA statues. Glucose is a main energy source for the body. In
hepatocytes, it is phosphorylated by hexokinase IV (glucokinase, GCK) to produce glucose 6phosphate. GCK is the first enzyme of hepatic glycolysis, and contributes to glucose homeostasis
in the body (211). Our previous studies have shown that retinoids and insulin synergistically induce
the hepatic Gck mRNA expression (212). Here, the reduction of VA status is associated with a
lowered Gck mRNA expression in ZL, but not ZDF, rats fed the BF or HF diets. This is an
interesting observation. Whether the elevated plasma insulin levels in ZDF rats mask the VA
effects on Gck mRNA expression remains to be investigated.
The expression levels of mRNAs and proteins in the fatty acid biosynthesis pathways were
reduced in VAD-HF ZDF rats. SREBP-1c regulates the hepatic cholesterol and fatty acid synthesis,
and induces the expression of FAS and ACL (213). The Srebp-1c mRNA of VAD-BF-ZL rats is
lowered than that of VAM/VAS-BF ZL rats. This change could not be observed in ZL fed a HF
diet or ZDF rats, suggesting the interactions of VA status with dietary fat content and genetic
changes. The increased expression levels of hepatic lipogenic genes, such as Srebp-1c, may be
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responsible for the higher plasma TG levels in VAS-BF/HF ZL/ZDF groups, which could also
explain the increased WAT/BM ratio of VAS-HF ZDF group.
The protein expression data in Western blot are largely consistent with the mRNA data
derived from real-time PCR. GCK, PEPCK, GS, and GSK-3β play a role in the regulation of
glucose metabolism. PEPCK and G6P are the enzymes involved in gluconeogenesis (214). GSK3β is a serine/threonine kinase that phosphorylates GS and inhibits glycogenesis (215). VA status
changes the protein levels of GCK, PEPCK, GS, and GSK-3 as shown in this study. GCK catalyzes
the conversion of glucose to glucose 6-phosphate, which can be used for glycolysis and glycogen
synthesis (216). The results shown here indicate that the liver GCK protein levels in the VAD-BF
ZL and VAD-HF ZDF groups were lower than those in the VAS-BF ZL and VAS-HF ZDF groups,
respectively. GSK-3β protein levels follow that same trend as GCK. In the VAM-BF ZL and VADBF ZDF groups, the protein levels of PEPCK, which involved in gluconeogenesis, are lower than
that in the VAS-BF ZL and VAS-BF ZDF groups, respectively. Interestingly, our previous study
found that there was no change in PEPCK levels in ZL rats fed a VAD diet with a normal fat
content compared with rats fed a VAS diet (204). Therefore, it suggests that VA status might
change the PEPCK levels in ZL and ZDF rats in the current experimental setting. The decreases
in the hepatic GCK and PEPCK levels may help to regulate glucose utilization in the liver of
VAD/VAM-BF ZL and VAD-BF/HF ZDF rats. Further studies are needed to determine the
mechanism by which VA status on the hepatic GCK and PEPCK levels in ZDF rats.
The hepatic levels of ACL, ACC, and FAS, which contribute to hepatic lipogenesis, are all
lowered in VAD-BF/HF ZDF group. The expression levels of hepatic genes involved in lipid
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metabolism are partly regulated by insulin (22). Compared with the VAS-BF ZDF group, the
higher IRβ protein levels in the liver of the VAD-BF ZDF group may indicate that the VAD-BF
ZDF group is more sensitive to insulin than the VAS-BF ZDF group. AGPAT2 catalyzes the
acylation of lysophosphatidic acid to phosphatidic acid, which is the precursor for the synthesis of
TGs and phospholipids (217, 218). The level of AGPAT2 protein indicates that ZDF rats have
increased lipogenesis. Therefore, reduced VA intake prevents obesity and T2DM in ZDF rats.
Regucalcin/SMP30 has been involved in the regulation and control of many basic biological
processes (cell growth, apoptosis, cell metabolism) (219). With the reduction of VA status, the
levels of Rgn mRNA and RGN levels of ZL and ZDF rats decrease, showing the impact of VA
status on the expression of genes beyond the glucose and lipid metabolism in ZL and ZDF.
5. Conclusion
In conclusion, T2DM has insulin resistance and hyperglycemia that relates to liver (220).
Therefore, insulin resistance is always related to

changes in the expression levels of hepatic

glucose and fatty acid metabolism genes (221). On the other hand, elevated TG levels will lead
to elevated free fatty acid levels, which may lead to insulin resistance and β-cell dysfunction
(222, 223). These results may accelerate the development of T2DM. This study shows that the
influence of VA status helps to regulate the expression of liver glucose and lipid metabolism
genes and proteins, and sufficient VA induce expressions of FAS, ACL, GCK and other
glucose and fatty acid enzyme genes and proteins in ZDF rats. VA also affects liver insulin
sensitivity at the level of IRβ protein expression. The results also support our previous
observation that VA status affects the weight gain of ZL and ZDF rats with different fat content
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(203, 206, 224). Due to the lack of VA, fatty acid synthesis in the liver of ZDF rats is reduced.
The effect of VA status on liver glucose metabolism can be adjusted by increasing dietary fat
intake. These findings indicate that reducing VA intake may have a protective effect on the
development of liver insulin resistance, which may help to find solutions to combat metabolic
diseases. The implication of these observations is that VA status may regulate glucose and fatty
acid metabolism, glycogen synthesis, and insulin resistance. More research is needed to
understand the role of VA in animal models and humans, especially in high dietary fat intake
conditions. Our research indicates that caution should be exercised when recommending VA
supplementation for obese or T2DM patients.
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Chapter Three
The Effects of RA and Insulin on the Expression of GLUT4 in
Differentiated L6 Myocytes
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Abstract
Glucose enters the skeletal muscle cells through GLUTs, a process that is stimulated by
insulin through the movement of GLUT4 to the cell membrane. Here, we studied the effects of
RA and insulin on GLUT4 expression in L6 muscle cells. First, we constructed a recombinant
adenovirus overexpressing GLUT4 protein (Ad-mGLUT4). We used Ad-mGLUT4 to identify
that EMD company’s GLUT 4 antibody was able to detect the correct band of GLUT4. Rat L6
muscle cells were treated without or with 1 μM RA in the absence or presence of 10 nM insulin
for 4 or 6 days. Cells were fractionated to prepare different lysates for analysis. 1) Cells were
lysed to get the supernatant and pellet or total lysate directly in 1 x SDS loading buffer. 2) Cells
were fractionated into cytosol, membrane and nuclear fractions. The GLUT4 protein levels in
these samples were determined via Western Blot. Results indicate that the lysis buffers tested
here may not completely solubilize differentiated L6 cells, suggesting the importance of cell
lysis methods and reagents in the analysis of membrane proteins. RA and/or insulin treatments
for 4 and 6 days affected GLUT4 expression and translocation. We conclude that RA affects
the expression of GLUT4 in differentiated L6 cells, suggesting the role of RA in the glucose
uptake in the muscle.
1. Introduction
VA is an essential lipophilic micronutrient, which is related to the regulation of glucose,
protein and lipid metabolisms (17). Retinol, which is derived from REs and provitamin A
carotenoids, is oxidized to retinal and then oxidized to RA by enzymes. RA exists in many isomeric

105

forms, such as all-trans RA and 9-cis RA. The main function of VA is mediated by RA (199). It
is important to understand the function of RA, because its signals affect glucose metabolism (199).
The skeletal muscle contributes significantly to glucose homeostasis (28-30). It uses glucose
and FAs as energy sources. It can also store glucose in the form of glycogen, or directly oxidize it
to produce energy after ingesting glucose under different metabolic conditions (9). Glucose enters
cells via the help of GLUTs that play an important role in regulating glucose sensing and metabolic
homeostasis (59). Insulin stimulation induces the movement of GLUT4 from cytosol to the cell
membrane (112). The increase in GLUT4 on cell membrane facilitates glucose entering cells.
GLUT4 is mainly expressed in adipocyte and skeletal muscle (66). It plays a key role in the insulinstimulated glucose uptake in the skeletal muscle (66). Therefore, understanding muscle glucose
metabolism and GLUT4 translocation is helpful to prevent the development of diabetes.
L6 muscle cells have been used to study the proliferation and differentiation of muscle cells
(225-227). It has been shown to respond to both RA and insulin in rat L6 skeletal muscle cells
(228, 229). RA can promote insulin-stimulated glucose uptake and increase GLUT4 mRNA levels
in L6 cells (229). The focus of our lab is to study the roles of VA in the regulation of glucose and
lipid, metabolic homeostasis. We have shown that the long-term treatment of RA and insulin
increases the glucose usage in L6 cells during differentiation, which is attributed to elevation of
glycogenesis (230).
The hypothesis of this study is that RA interacts with insulin in the regulation of GLUT4
expression in L6 cells. Here, the effects of RA and insulin on GLUT4 expression in differentiating
L6 muscle cells were studied. L6 cells were treated with RA alone or with insulin during
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differentiation for 4 and 6 days. The expression levels of GLUT4 in the total cell lysates, pellets,
and cell fractions were determined after validation of the anti GLUT4 antibodies using a
recombinant adenovirus overexpressing GLUT4.
2. Materials and Methods
2.1 Reagents
For cell culture and L6 rat skeletal muscle differentiation, Dulbecco's Modified Eagle
Medium (DMEM), and penicillin/streptomycin (P/S) were purchased from Mediatech (Manassas,
VA, U.S.A.). Fetal bovine serum (FBS) was purchased from Life Technologies (Grand Island, NY,
U.S.A.). Horse serum (HS) was purchased from Hyclone Laboratories (Logan, UT, U.S.A.).
Insulin and all-trans retinoic acid (RA, diluted in ethanol) were purchased from Sigma Aldrich
Corporation (St. Louis, MO, U.S.A.). The BCA protein assay kit was purchased from Pierce
Biotechnology, Inc (Rockford, IL, U.S.A.) for the determination of the protein concentration.
Immobilon-PSQ PVDF membrane was purchased from EMD Millipore Corp (Billerica, MA,
U.S.A.). Non-fat dry milk of Food Club was purchased from to a grocery store and was used to
block membrane and to prepare antibodies. Bovine serum albumin (BSA) protease-free powder
was purchased from Fisher BioReagents™ to make the second antibody. Table 3-1 summarized
the sources, catalog number, description of, and expected sizes of the detected proteins by the
antibodies tested in this study. For immunoblotting, GLUT4 antibody (C-terminus) was purchased
from EMD Millipore Corp (Billerica, MA, U.S.A.). β-Actin (#4970) antibodies and Goat antirabbit IgG conjugated to horseradish peroxidase (#7074) secondary antibody were purchased from
Cell Signaling Technology (Danvers, MA, U.S.A.). ECL Western Blotting Substrate was
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purchased from Pierce Biotechnology, Inc (Rockford, IL, U.S.A.), which was used to visualize the
recognized proteins.
2.2 Cultures of HEK 293, HL1C, and L6 cells
Rat L6 cells were cultured as described in (230). L6 cells in 60 mm dishes were maintained
and sub-cultured in DMEM with 4.5 g/L (25 mM) glucose supplemented with 10% FBS + 1%
penicillin/streptomycin at 37°C and 5% CO2. When cells reached ~100% confluence, the cell
medium was changed to DMEM containing 25 mM glucose with 2% HS + 1%
penicillin/streptomycin to induce differentiation. To study the effects of RA and insulin on GLUT4
expression in differentiated L6 muscle cells, L6 cells at confluence were induced to differentiation
in media with 2% HS containing control or 1uM RA with or without 10 nM insulin for 4 or 6 days.
Fresh media containing the same reagents were changed every two days.
The HEK293 cells were cultured in DMEM containing 4.5 g/L (25 mM) glucose with 10%
FBS + 1% penicillin/streptomycin at 37°C and 5% CO2. When cells reached 50~80% confluence,
the cell medium was changed to growth medium without serum and antibiotics one day before
transfection. The HL1C rat hepatoma cells were cultured in DMEM containing 4.5 g/L (25 mM)
glucose with 5% FBS + 1% penicillin/streptomycin at 37°C and 5% CO2.
2.3 Construction of the Recombinant Adenovirus Overexpressing GLUT4 (Ad-mGLUT4)
To find a positive control to evaluate GLUT 4 antibodies from different companies, we
decided to construct a recombinant adenovirus overexpressing GLUT 4 protein. The recombinant
and replication-deficient adenovirus was generated via homologous recombination (231).
The pCMV3-mSLC2A4-HA (Cat# MG57001-CY) plasmid was obtained from Sino
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Table 3-1: Summary of GLUT 4 antibodies used in this chapter
Companies

Catalogue Number Description

Molecular Weight

EMD Millipore Corp

#07-1404

~58 kDa

C-terminus,
1:1,000 dilution for western blotting analysis

Santa Cruz Biotechnology

SC-53566, #G1017

mouse monoclonal

50-63 kDa

1:1,000 dilution
Bioss Antibodies

bs-0384R-FR

Rabbit Polyclonal

~50 kDa

Cell Signaling Technology

#2213S

Mouse IgG1

50 kDa

Sino Biological

#100733-T42

Polyclonal Rabbit IgG against human C-terminus, 54 kDa
, 1:1,000 dilution

Bethyl Laboratories

A304-377A-T

Polyclonal Rabbit IgG, 1:1,000 dilution
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~70 kDa

Biological (Chesterbrook, PA). The mouse Slc2a4 cDNA was inserted into plasmid pACCMV5
as shown in Figure 3-1. A DNA fragment containing the mouse Slc2a4 cDNA was released from
pCMV3-mSLC2A4-HA after digestion with KpnI and XbaI. The fragment with the Slc2a4 cDNA
was inserted into the vector pACCMV5 digested by the same enzymes to obtain plasmid
pACCMV5-mSLC2A4. After that, equimolar amounts of pACCMV5-mSLC2A4 (0.4 μg) and the
plasmid pJM17 (1.6 μg) were co-transfected into HEK 293 cells using lipofectin reagent
(Invitrogen). pJM17 is a plasmid contains a full-size, circular adenovirus genome, and 293 cells
are engineered cells for the recombinant adenovirus to replicate and pack viral particles.
Transfected HEK 293 cells were incubated in DMEM containing 2% FBS at 37°C and 5% CO2
until plaques were formed due to the cell lysis. The generation of recombinant adenovirus occurred
about 10 to 20 days after the transfection. After that, the lysed cells and media were collected as
stocks, and stored at -80°C. This mixture was frozen and thawed twice to obtain crude lysates,
which contains Ad-mGLUT4.
To generate crude lysate, HEK 293 cells were grown at 70-80% confluence in 100 mm tissue
culture plates and were infected with the original crude lysate containing Ad-mGLUT4. The ratio
of medium to crude lysate is 10:1. The cells are lysed approximately 48 hours after infection, and
the cell culture medium (crude lysate) is collected and stored at -80°C until use.
2.4 Detection of GLUT4 Proteins in the Total Lysates of Ad-mGLUT4 Infected cells
After Ad-mGLUT4 was obtained, 500 µl of crude lysate were add to 293 cells or HL1c cells
at 100% confluency in each 60 mm dish which contained 4 ml DMEM culture medium. Cells were
incubated at 37°C and 5% CO2 for 24 hours. Then, 400 µl of 1 x SDS loading buffer was added
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Figure 3-1: Schematic of production of recombinant adenovirus, Ad-mGLUT4.
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in one 60 mm dish to directly lyse the cells and obtain the total cell lysate. For the analysis of
transgenic expression in Western blot, 30 ul of total lysate of transfected or untransfected cells
were loaded into each well in 10% SDS-page gels for protein separation.
To determine the GLUT4 expression in L6 cells, membrane fraction from L6 muscle cells
treated in absence or presence of 1μM RA without or with 10 nM insulin for 6 days were used to
analyze antibodies from different companies.
2.5 Lysis of L6 Rat Skeletal Muscle Cells
2.5.1 Preparation of the Whole Cell Lysates of L6 Cells Treated without or with 10 nM
Insulin in the Absence or Presence of 1μM RA for 4 or 6 Days (Method A)
For whole cell lysis experiment, L6 cells at 100% confluence were incubated in media with
2% HS containing in the absence or presence of 1μM RA with or without 10 nM insulin for 4 or 6
days. Fresh media with the indicated reagents were replaced every two days. Then, L6 cells were
lyzed in lysis buffer (50 mM HEPES pH 7.5, 10 mM EDTA, 10% Glycerol) containing 1% NP40 and 1% Triton X-100 (Lysis Buffer A) or 2% NP-40 and 2% Triton X-100 (Lysis Buffer B)
with or without 40 strokes of Dounce homogenizer to ensure that L6 muscle cells can be
completely lysed (Method A). The lysate was centrifuged at 12,000 x g for 15 minutes at 4°C for
the collection of the supernatant (contain cell membrane, cytoplasmic and nuclear proteins), which
was named the Whole Cell lysate and used to determine GLUT4 protein level by Western blot
(Figure 3-2).
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Figure 3-2: Methods to lysates L6 cells treated with media without or with 10 nM insulin in the absence
or presence of 1μM RA for 4 or 6 days.
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2.5.2 Preparation of the Whole Cell Lysates of L6 Cells Treated without or with 10 nM
Insulin in the Absence or Presence of 1μM RA for 4 or 6 Days (Method B)
To study the distribution of GLUT4 in the cell fractions, differentiating L6 cells were treated
without or with 10 nM insulin in the absence or presence of 1μM RA for 4 or 6 days were lyzed
in two methods (Method B) as shown in Figure 3-3. 1) Four hundred ul of lysis buffer B containing
50 mM HEPES pH 7.5, 10 mM EDTA, 10% Glycerol, 2% NP-40 and 2% Triton X-100 was added
to each 60 mm dish. Cells was scraped to a microcentrifuge tube and kept on ice for 20 minutes
with vortex every 10 minutes to enhance lysis process. After that, the lysate was centrifuged at
12,000 x g for 15 minutes at 4°C for the collection of both the supernatant and pellet. Pellets were
directly lysate in three hundred ul 1x SDS loading buffer. 2) To obtain the complete total cell
lysate, L6 cells after the indicated treatments were directly lyzed in 500 µl 1 x SDS loading buffer
(Figure 3-3).
2.5.3 Preparation of Subcellular Fractions of Rat L6 Cells treated without or with RA in
the absence or Presence of 10 nM Insulin for 6 Days (Method C)
To find out a better way to lyze differentiating L6 cells and analyzes the effects of insulin and
RA in translocation of GLUT4, L6 cells were fractionated to obtain cytosol, membrane and nuclear
subcellular fractions. When L6 cells reach to 100% confluence, we differentiated them in the
presence or absence of RA with or without insulin for 6 days. As shown in Figure 3-4, L6 cells
were lysed in 1 ml of buffer C (20 mM HEPES pH 7.6, 0.3 M Sucrose, 10 mM NaCl, 1.5 mM
MgCl2, 0.5% NP40, 1 mM Spermidine) and homogenized after 20 strokes using a Dounce
homogenizer on ice. Then the lysate was centrifuged at 500 x g for 10 minutes at 4°C and collect
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Figure 3-3: Methods to obtain lysates of L6 cells treated with media without or with 10 nM insulin in the
absence or presence of 1μM RA for 4 or 6 days.
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both supernatant and pellet, pellet were lysis by adding 300 µl of lysis buffer D (20 mM HEPES
pH 7.6, 1.5 mM MgCl2, 1M DTT, 0.5 M NaCl, 1 mM EDTA pH 7.6, 1 mM EGTA pH 7.6, 25%
Glycerol) and store on ice for 30 mins, then centrifuged at 100,000 x g for 30 minutes at 4°C to
obtain supernatant as nuclear extract. The supernatant which should contain cytosol and membrane
was centrifuged at 55,000 x g for 30 minutes at 4°C to obtain supernatant as cytosol and pellet as
membrane. Membrane pellet was solubilized by adding 200 ul of membrane lysis buffer E (10 nM
Tris HCl pH 6.8, 100 mM NaCl, 1% SDS). After the centrifugation, the upper part of supernatant
was cloudy. Therefore, the supernatant of cytosolic faction was collected as the upper cytosol and
lower cytosol fractions.
2.6 Protein Isolation, Determination, and Immunoblotting (Western Blot)
All cell dishes were kept on the ice and then culture medium was pumped out through aspiration.
Cells were washed once on ice with 3 ml Phosphate-buffered saline (PBS) before being lysed as
described in the previous sections. The protein concentrations in the cell lysates and fractions were
determined with PIERCE BCA protein assay kit (Rockford, IL). Reagent A was mixing with
reagent B (50:1) to make working reagent. Five μl of each cell lysate protein was add into 495 ul
dd H2O in centrifugation tubes separately to get a finally 500 ul sample. The standard protein stock
(2 mg/mL) was diluted to 0, 5, 10, 20, 40, and 80 ug/uL for making standard curve. In 1 ml reaction,
500 μl of the working reagent and 500 ul sample/standard protein sample was added together. The
reaction was incubated in 37°C for 30 mins then a triplicate of 300 ul per well was added to a 96
well plate. OD reading at 560 nm was measured on a 96-plate reader (GloMax®-Multi Detection
System (Promega, Madison, WI). A standard curve was prepared by plotting the average blank116

Figure 3-4: GLUT4 expression levels in cytosol, membrane and nuclear fractions of L6 treated without or
with 1uM RA in the absence or presence of 10 nM insulin for 6 days.
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corrected 560 nm OD readings vs. the concentrations in μg/mL. A formula derived from regression
was obtained and used to determine the total protein concentration of each sample. The final
protein concentration of each sample was adjusted to 2μg/ul. The concentration adjusted protein
sample and loading buffer were mixed and incubated in water bath at 100°C for 10 minutes. The
resulted loading samples were stored at -20°C until being used.
For Western blot, 40 µg proteins of each sample were loaded to each well and separated on
10% SDS-PAGE gels. The separated proteins were transferred from gel to a PVDF membrane,
which was blocked with 5% milk diluted in 1x TBST (Tris-buffered saline with 0.1% Tween) at
room temperature for one hour. The primary antibodies were diluted in TBST containing 5% BSA
or dry milk according to the manufactures’ instructions. The membrane was incubated in the
primary antibody at 4 °C for overnight. The membranes were washed three times with 1x TBST,
5 minutes each time after overnight incubation. The second antibody was diluted in 5% milk in 1x
TBST (1:1000) and the membrane was incubated in the second antibody for one hour at room
temperature. The membrane was washed again for three times with 1x TBST (5 minutes each time).
After that, ECL Western Blotting Substrate was used to cover the membrane for visualization of
the protein bands. Konica SRX 101A Film Processor was used to develop the film.
Quantification analysis was performed on Image J software (NIH, Bethesda, Maryland, USA).
The density of a protein band was calculated by subtracting the background in an area of the same
size near it. Then, the ratio of the densities of the indicated protein to that of the control protein
(indicated protein/β-actin) was calculated for quantification.
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2.7 Statistical Analysis
All experiments were repeated for three times. One-way ANOVA with LSD post-hoc
statistical analysis was conducted using GraphPad Prism 8.0 (GraphPad Software, Inc., San Diego,
CA). Data were presented as means ± S.E.M. The difference was considered significant when the
p-value was less than 0.05.
3. Results
3.1 Anti GLUT4 antibodies from different sources detected distinct bands in Western blot
To evaluate which antibody can detect the correct GLUT4 protein bands at right molecular
weight, GLUT 4 antibodies from different companies were compared using the same set of
membrane preparations of L6 cells treated with or without 1 µM RA in the absence or presence of
10 nM insulin for 4 days, which were prepared by Method A. The same set of samples were loaded
on the same gels for comparing the proteins detected by GLUT4 antibodies (Table 3-1) in Western
Blot. As shown in Figure 3-5, GLUT4 antibodies from different sources detected protein bands
with different molecular masses and at different locations in the same membrane fractions of L6
cells. The antibody from EMD Millipore Corp detected a band at about 56 kilodalton (kDa) in
contrast to its predicted molecular weight (MW) of 58 kDa. The antibody from Santa Cruz
Biotechnology detected a band at 43 kDa in contrast to its predicted MW of 50~63 kDa in the
product description. The antibody from Bioss Antibodies detected a band at 56 kDa in contrast to
its predicted MW of 55 kDa in their product description. The antibody from Cell Signaling
Technology detected multiple bands and the strongest band detected at 43 kDa in contrast to its
predicted MW of 50 kDa in their product description. The antibody from Sino Biological detected
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a band at 72 kDa in contrast to its predicted MW of 54 kDa in their product description. The
antibody from Bethyl Laboratories detected a band above 43 kDa in contrast to its predicted MW
of 70 kDa in their product description (Table 3-2).
3.2 Confirmation of GLUT4 Proteins in Lysates of Ad-mGLUT4 Infected Cells
To establish a positive control for the evaluation of GLUT 4 antibodies from different
companies, mouse Slc2a4 cDNA was obtained and inserted into pACCMV5 to produce
recombinant adenovirus Ad-mGLUT4 as described in the Materials and Methods section. To
confirm that we have successfully obtained Ad-mGLUT4, the GLUT4 protein levels in the whole
cell lysates of 293 and HL1C cells uninfected or infected with four batches of Ad-mGLUT4 crude
lysates were determined using EMD’s anti-GLUT4 antibody in Western blot. The total cell lysates
of 293 and HL1C cells without infection did not show any GLUT4 protein expression. Compared
to that of the uninfected cells, total cell lysates of Ad-mGLUT4 transfected cells clearly showed
the overexpression of GLUT4 at 56 kDa (kilodalton) molecular weight (Figure 3-6).
3.3 Evaluation of anti GLUT4 antibodies using total cell lysates of 293 cells without or
with infection of Ad-mGLUT4
Anti-GLUT4 antibodies from different companies were compared using the same set of
whole cell lysate of 293 cells with or without transfection of Ad-mGLUT4. These samples were
shown to have GLUT4 overexpression in the previous section. As shown in Figure 3-7, those antiGLUT4 antibodies from different companies still detected an anticipated and overexpressed band
of GLUT4. Compared to the results obtained using EMD company’s antibody (Figure 3-7A), the
same band was detected at the same location in the Ad-mGLUT4 transfected 293 cells by
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Figure 3-5: GLUT4 antibodies from indicated companies detect protein band at different location in L6
cell lysate in western blot experiment. A: EMD Millipore Corp (#07-1404) shows band at about 56 kda; B:
Santa Cruz Biotechnology (SC-53566, #G1017) shows the band at 43 kda; C: Bioss Antibodies (bs-0384R-FR)
shows band at 56 kda; D: Cell Signaling Technology (#2213S) shows multiple band and the strongest band dected
at 43 kda; E and F: Sino Biological (#100733-T42) shows the band at 72 kda; and G: Bethyl Laboratories (A304377A-T) detected a strongest band above 43 kda.
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Table 3-2: Summary of GLUT4 antibodies in detected vs. predicted molecular weight

Company name
EMD Millipore Corp (#07-1404)
Santa Cruz Biotechnology (SC-53566,
#G1017)
Bioss Antibodies (bs-0384R-FR)
Cell Signaling Technology (#2213S)
Sino Biological (#100733-T42)
Bethyl Laboratories (A304-377A-T)

Detected molecular
weight (kDa)
56
43

Predicted molecular
weight (kDa)
58
50~63

56
Multiple bands and the
strongest band at 43 kDa
72
Above 43

55
50
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54
70

Figure 3-6: Comparing GLUT4 expression level in transfected and untransfected 293 or HL1c cells using
EMD antibody in western blot.
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antibodies from companies except for that from Bioss (Figure 3-7C), which detected an
overexpressed band nearly at 72 Kda. The antibodies from Santa Cruz Biotechnology (Figure 37B) and Cell Signaling Technology (Figure 3-7D) seemed to show less interaction with the
overexpressed GLUT4. All these results indicate that EMD company’s antibody detected the
correct size band in membrane fraction of L6 cells and whole cell lysates of 293 cells (which do
not express GLUT4) transfected with Ad-mGLUT4. Therefore, the EMD company’s antibody was
selected to use in the following experiments.
3.4 GLUT4 Levels in L6 Cells Treated without or with 10 nM Insulin in the Absence or
Presence of 1μM RA for 4 or 6 Days in Whole Cell Lysates Prepared using Method B
The effects of treatments of RA and insulin for 4 or 6 days on the protein expression of
GLUT4 in differentiating L6 cells in supernatant, pellet and total cell lysates were studied. Cells
were lysed using Method B. As shown in Figure 3-8, a representative blot of GLUT4 in L6 cells
treated in the absence or presence of 1μM RA without or with 10 nM insulin for 4 days.

The

supernatants obtained from cells treated with insulin alone or with RA for 4 days had significantly
less GLUT4 protein levels than that of the control group. The pellets of L6 cells treated with RA
alone had significantly less GLUT4 expression than the control group, and that treated with insulin
alone or insulin with RA had significantly higher GLUT4 protein levels than that of the control
group and RA alone group. The GLUT4 protein levels in total cell lysates of the insulin + RA were
significantly higher than the control group and RA alone group (Figure 3-8).
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Figure 3-7: GLUT4 antibodies from different companies detect GLUT4 protein overexpressing in lysis of
293 cell with or without Ad-mGLUT4. A: EMD Millipore Corp; B: Santa Cruz Biotechnology; C: Bioss
Antibodies, D: Cell Signaling Technology; E: Sino Biological; F: Bethyl Laboratories.
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Figure 3-8: The GLUT4 protein levels of rat L6 muscle cells in the absence or presence of 1μM RA without
or with 10 nM insulin for 4 days in Different Preparation Lysates. Data were expressed as mean ± SEM for
three independent experiments; */#p<0.05, for comparing the indicated group and the control group or RA group;
**/## p<0.01, for comparing the indicated group with the control group or RA group.
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The supernatant of cells treated with insulin + RA for 6 days had significantly less GLUT4
protein levels than all other groups. The pellets of cells treated with insulin alone or insulin + RA
had significantly higher GLUT4 protein levels than that of the control group and RA alone group.
The GLUT4 protein levels in total cell lysates were not significantly different among the four
treatment groups (figure 3-9).
In summary, given the fact that the GLUT4 protein levels in the supernatants and pellets of
differentiating L6 cells were affected significantly by the treatments with RA and/or insulin for 4
and 6 days. Both 10 nM Insulin and 1 μM RA reduce the levels of GLUT4 in supernatants of L6
cells treated for 4 and 6 days. Interestingly, there appears to be an interaction between RA and
insulin. By comparing the GLUT4 protein levels in different lysates, a significant amount of
GLUT4 protein remained in the pellets of the total cell lysate prepared in buffer B using method
B. It indicates that the lysis buffer B used here might not completely solubilize differentiating L6
muscle cells, and methods should be chosen carefully for the analysis of GLUT4 protein.
3.5 Rat L6 Cells in the Absence or Presence of 1μM RA Without or with 10 nM Insulin
for 6 Days in different subcellular fractions prepared by Method C
The differentiating L6 cells treated with or without RA in the absence or presence of insulin
for 6 days. The protein levels of GLUT4 in membrane and nuclear fractions prepared by Method
C of cells treated with RA alone and RA+ insulin groups were significantly higher than that in
the control group. GLUT4 in the membrane fraction of L6 cells treated with insulin + RA was
significantly higher than all other groups. In nucleus, GLUT4 of insulin + RA group is
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Figure 3-9: The GLUT4 protein levels of rat L6 muscle cells in the absence or presence of 1μM RA without
or with 10 nM insulin for 6 days in Different Preparation Lysates. Data were expressed as mean ± SEM for
three independent experiments; */#p<0.05, for comparing the indicated group and the control group or RA group;
& p<0.05, for comparing the indicated group with Insulin + RA group.
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significantly higher than that of insulin alone group. There is no significant difference of GLUT4
expression levels among the four treatment groups in cytosol (Figure 3-10).
4. Discussion
The purpose of this study is to understand how RA affects the glucose metabolism in L6
skeletal muscle cells as we have observed elevation of glucose usage in L6 cells treated with RA
and insulin previously (230). Here, we set up experiments to study the impacts of RA and insulin
treatments on the GLUT4 expression levels in L6 cells during the differentiation process.
However, we encountered challenges of lacking a validated anti GLUT4 antibody for the use in
Western blot. Therefore, we constructed a recombinant adenovirus to overexpress mouse
GLUT4 (Ad-mGLUT4), and evaluated the GLUT4 expression levels in L6 cells using the
validated antibody.
Anti-GLUT4 antibodies from various sources have been used to study GLUT4 expression
and translocation. The conclusions of the study are based on experimental results using these
antibodies. As shown in Figure 3-5, anti GLUT4 antibodies from different companies detected
bands with different molecule masses in Western blot. It is apparent that the lack of a control to
indicate the correct band in Western blot was the problem. In 2016, the International Antibody
Verification Working Group held a meeting to emphasize the necessity of verifying antibodies in
common research applications (232). A positive control from a cell or tissue with unique
overexpression or silencing of GLUT4 is essential to confirm the specificity of the antibody to
obtain the correct signal in the research system. This is especially true for Western blotting. It
may be necessary to confirm the specificity of the antibody in a particular system first. The data
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Figure 3-10: The GLUT4 protein levels of rat L6 muscle cells in the absence or presence of 1μM RA without
or with 10 nM insulin for 6 days in cytosol, membrane and nucleus. Data were expressed as mean ± SEM for
three independent experiments; */#p<0.05, for comparing the indicated group and the control group or Ins+RA
group; **/## p<0.01, for comparing the indicated group with the control group or Ins+RA group.
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indicate in our limited survey, some of commercial antibodies failed to detect GLUT4 at correct
location or recognized a nonspecific protein. We have summarized the studies using antibodies to
study GLUT4 expression and translocation (233). Some of the studies did not use cells or tissue
samples with deletion or overexpression of GLUT4 as a negative or positive control, respectively.
Therefore, we should be cautious when a conclusion was drawn based on a study without this kind
of controls.
To solve practical problems related to GLUT4 antibodies, we have produced Ad-mGLUT4.
Adenovirus transfer vectors have a wide range of uses and applications (234). Recombinant
adenoviruses have a high efficiency of gene transfer in broad species and cells. They can be used
for in vitro protein expression and purification, research on the effect of gene products on cell
biology, or in vivo research on multiple tissue types and multiple different species (235). Driven
by CMV promoter, a very high level of expression of recombinant proteins can be achieved by
recombinant adenoviruses (235). Although it has been found that adenoviral vectors can infect a
variety of mammalian cells, not all cells allow infection. The expression of adenovirus genes
occurs in two stages, early and late. The early genes are encoded by four different transcription
units early regions E1-E4 (236). In most recombinant vectors, a foreign gene is inserted as a
substitute for the E1 or E3 region. The replacement of the E1 region will result in a replication
defective vector; E3 is involved in evading host immunity and is not necessary for virus production
(236). Human embryonic kidney cells (HEK293) provide E1 to complement the defect of viral
replication (236). Therefore, in this study we use HEK293 cells to obtain the recombinant
adenovirus Ad-mGLUT4. We used 293 and HL1C cells to confirm that we have successfully
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constructed Ad-mGLUT4.
Based on GLUT4 protein bands detected in the lysates of 293 cells with or without infection
of Ad-mGLUT4by antibodies from different companies, EMD company’s antibody appears to
offer the best quality. It detects the same band in L6 cells and 293 or HL1C cells with GLUT4
overexpression. GLUT4 antibodies from other companies detect multiple bands or a band that is
not at the correct location. Currently, researchers rely on antibodies company or other online
resources when selecting antibodies. However, the quality of technical support provided by
different companies varies greatly. Sometimes, the antibody detects unexpected increase of the
band(s) that is not at the correct location. Therefore, misinterpretation of the research findings and
poor reproducibility can occur without validation of the commercially available antibodies.
GLUT4 protein expression is a key factor in skeletal muscle glucose metabolism. Insulin is
an important hormone that regulates skeletal muscle glucose metabolism. Both the expression of
GLUT4 and the translocation of GLUT4 can be regulated by insulin (66, 237). Insulin can
stimulate the mobilization of GLUT4. When the GLUT4 level in the plasma membrane increases,
its level in cytosol decreases. As shown in Figures 3-8 and 3-9, insulin and RA + insulin treatments
for 4 and 6 days appears to inhibit the levels of GLUT4 protein in supernatants of L6 skeletal
muscle cells during differentiation prepared by Method B. However, GLUT4 levels of the pellets
(insoluble fraction) in cells treated with insulin and RA + insulin groups are increased in
comparison with that in the control or RA group. On the other hand, the total GLUT4 levels in the
L6 cells treated with insulin or RA+ insulin for 4 days and lysed in 1 x SDS loading buffer are
higher than that in the control cells. A challenge facing biochemical study of GLUT4 translocation
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in the muscle may be the sample preparation. When the differentiated L6 muscle cells were lysed
using the traditional whole-cell lysate method, we found that the large amount of GLUT4 protein
remains in the pellets. This indicates that the lysis buffer used here may not completely dissolve
the differentiated L6 muscle cells. These results indicated that lysis buffer used in the preparations
of whole cell lysates are crucial for the detection of GLUT4. The insulin treatment causes GLUT4
to stay in the insoluble pellet in our current experimental setting. Whether this insoluble structure
is the real insulin-induced functional unit for glucose transport remains to be determined.
The skeletal muscle is made of many muscle fibers connected by connective tissue, which
makes it difficult to dissolve in whole cell lysis buffer. The lysis Method C and buffers C, D and
E used here might solubilize differentiating L6 cells efficiently, and can be used to analyze GLUT4
protein expression. The GLUT4 protein level in the cytosol is more difficult to be detected than
that in membrane and nucleus. This probably due to that fact that GLUT4 is a protein associated
with membrane all the time. Therefore, the amount of GLUT4 in cytosol is difficult to be detected.
The nucleus probably may contain unfractionated or unbroken cells. Data shown in Figure 3-10
did not include the total cell lysate, which is something that we will perform in the future.
Nevertheless, the GLUT4 protein levels in the membrane of differentiating L6 cells prepared by
Method C and in buffer E were affected significantly by the treatments with RA and/or insulin.
In the future, to study the effects of RA and insulin on the subcellular movement of GLUT4
in differentiating L6 muscle cells, the total cell lysate should be included as a control group. It will
help to compare GLUT4 levels in different subcellular fractions. Since a significant amount of
GLUT4 protein can be detected in the nucleus, it probably means that there are still cells that are
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not completely broken in the current experimental setting. Therefore, more strokes of Dounce
homogenizing might be needed to lyse and separate the cells into different fractions.
5. Conclusion
We have constructed the Ad-mGLUT4 recombinant adenovirus, which allows us to
overexpress GLUT4, and successfully determine a functional anti GLUT4 antibody for our
study. This Ad-mGLUT4 can be a useful tool to study the GLUT4 expression and translocation
in L6 muscle cells treated with RA and insulin in the future. In addition, we have successfully
determined the ideal method and lysis buffer that can be used in L6 cells. RA appears to interact
with insulin to affect the expression and translocation of GLUT4 in L6 muscle cells during
differentiation. This interaction may contribute to the elevated glucose usage in L6 cells treated
with RA and insulin as shown in (230). All these have set up a stage for more future studies,
which will help us to understand the role of VA in the regulation of glucose metabolism and in
GLUT4 translocation in L6 cells.
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Chapter Four
Conclusions and Future Directions
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1. Conclusion
The prevalence of metabolic diseases such as T2DM has become a public health problem
(36). Skeletal muscle plays a key role in regulating glucose and metabolic homeostasis (28). In
this dissertation, we have demonstrated that VA contributes to glucose and lipid metabolisms
in vivo and in vitro. The goal of our lab is to find the effect of VA and dietary factors on glucose
and lipid metabolisms in the whole body and liver, and the effect of VA on glucose metabolism
in skeletal muscle cells with or without insulin. Specifically, we have used ZDF rats, a genetic
model of T2DM, and rat L6 skeletal muscle cells to understand these two questions. (1) Does
VA status affect the physiological functions and liver glucose and lipid metabolism of ZL and
ZDF rats, and the development of T2DM in ZDF rats? (2) Does RA alone and in combination
with insulin affect the expression level of GLUT4 in L6 skeletal muscle cells? The answers to
these two questions are described in Chapters 2 and 3, which can provide insight into the
mechanisms by which VA affects metabolism. The results presented in this dissertation will
help us to find ways to intervene obesity and T2DM.
In Chapter 2, we investigated the effects of VA status and dietary fat content (BF or HF)
on morphometrics, plasma biochemical markers, and hepatic expression levels of genes and
proteins for glucose and lipid metabolism in ZL and ZDF rats, and obtained the following
results. First, VA status affects food intake in both ZL and ZDF rats. The development of VAD
will cause a reduction of appetite in ZL and ZDF rats. In addition, rats fed a VAM, or VAS diet
gain more BM than those fed the VAD diet. The effects of VA status on the BM gain in both
ZL and ZF rats fed a HF diet appeared at 4 weeks on the diet compared to those fed a BF diet
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at 6 weeks, suggesting an interaction between VA and dietary fat content. Second, ZDF rats
fed a VAS-BF or a VAS-HF diet will development hyperglycemia after 5 weeks on the diets.
Interestingly, the PBG levels in VAM-HF ZDF group were lower than VAD/VAS-HF ZDF
group during OGTT, demonstrating the potential benefit of limiting the VA intake in ZDF rats
to attenuate T2DM development. The ITT and OGTT data indicate insulin resistance and
impaired glucose tolerance in VAS-HF and VAS-HF ZDF rats. Third, the ratios of liver and
WAT to BM, plasma glucose, TG, cholesterol, insulin, and leptin in ZDF rats fed the
VAD/VAM diets are lower than that of fed the VAS diet regardless the fat content. Fourth, the
ZL rats in the VAD-BF ZL group have lower hepatic Gck, Srebp-1c, Scd1, G6p, and Rgn
mRNA levels, and higher hepatic Srebp2, CD36 and Igfbp1 mRNA levels than those in the
VAM/VAS-BF groups. The mRNA levels of Fas, Acl, Scd1, CD36, G6p, and Rng in the liver
of VAS-HF ZDF group were increased compared with that of VAD/VAM-HF groups. The
hepatic mRNA levels of Pck1, Raldh1, and G6p in ZDF rats of the VAM-HF group were lower
than that of VAD/VAS-HF groups. All these demonstrated clearly that VA contributes to the
control of hepatic expressions of genes for glucose and lipid metabolism as we have shown
previous in ZF rat studies (200, 203, 204, 206) . Fifth, the lack of VA suppresses the hepatic
protein levels of ALC, IRβ, GCK, GS, GSK-3β, and RGN in rats of the VAD-BF group, and
ACC, FAS, ACL, RGN, and AGPAT2 in ZDF rats of the BF/HF groups, and induces the
protein levels of IRβ and GS in ZL rats of the HF group. The feeding of the VAM diet induces
the hepatic IRβ and GS protein levels in ZDF rats of the HF group. All these observations show
that VA status affects the expression levels of hepatic genes for glucose and lipid metabolism
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in the liver ZDF rats, especially those fed a HF diet.
In Chapter 3, we investigated the effects of RA and insulin on GLUT4 expression in L6
muscle cells and obtained the following results. First, we observed that antibodies from
multiple sources detect different bands on the Western blot membrane. This indicates that we
could not rely on the “specificity” of an antibody to study the endogenous GLUT4 expression
in L6 cells without validating the antibodies. A positive control group is needed to screen the
antibodies from different sources. We successfully constructed the Ad-mGLUT4 recombinant
adenovirus, which overexpresses mouse GLUT4 in cells. This allowed us to successfully
determine a functional anti GLUT4 antibody for our study. Second, we encountered another
problem which is to lyse muscle cells for the study of GLUT4 levels and its subcellular
localizations. We have tested multiple buffer and methods to lyse and fractionate L6 cells. We
have successfully determined methods that can help us to analyze the GLUT4 levels in total
cell lysates and fractions. Insulin and RA + insulin treatments for 4 and 6 days appear to inhibit
the levels of GLUT4 protein in supernatants of L6 skeletal muscle cells during differentiation
prepared by whole cell lysates (Method B, and Lysis Buffer B). Third, the GLUT4 protein
levels of differentiating L6 cells prepared by fractionated lysates were affected significantly by
the treatments with RA and/or insulin. Collectively, in rat L6 skeletal muscle cells, RA and/or
insulin treatment influence the levels of GLUT4 in different cell fractions.
2. Future Directions
This dissertation investigated that reducing the VA status can alleviate hyperinsulinemia,
hyperglycemia and hyperleptinemia in ZDF rats. The potential mechanism of VA status in
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regulating liver glucose metabolism and glycogenesis is worthy of further study, and may help
to assess the effect of VA on the development of T2DM in patients. Also, Ad-mGLUT4 may
be a useful tool to study GLUT4-mediated glucose transport in skeletal muscle cells.
2.1 Animal studies
According to our experimental results about the effects of VA on the development of
obesity development published previously using ZF rats (200, 206) and T2DM shown in this
dissertation, it is suffice to say that supplementation of VA in patients with obesity and diabetes
is something that should be considered cautiously and seriously. In addition, our observations
also raise more questions about the underlying molecular mechanisms. We believe that the
following research areas are worthy of further research.
The expression levels of hepatic genes involved in glucose and lipid metabolism are at
least partially regulated by the action of insulin (22). We determine the protein hepatic
expression levels of IRβ, which are reduced in VAS-BF/HF groups compared with that in
VAD/VAM groups of ZDF rats, respectively. This probably reflects the difference of plasma
insulin levels of these rats. Whether long term hyperinsulinemia in VAS ZDF rats is responsible
for this reduction remains to be determined. Therefore, the effect of VA status related to the
insulin sensitivity of ZDF rats is worth to be investigated further.
We obtained two pairs of heterozygous Zucker rats from the vender and established a
breeding colony of Zucker rats by ourselves. The experimental rats received the treatments
according to the date of their birth. One interesting phenomenon is that ZDF rats born at a later
litter appear to develop hyperglycemia and get diabetes quicker or at a relative younger age
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than those born at an earlier litter. This happens when the environmental conditions in the
animal facility were supposed to be unchanged. If we assume that the animal facility conditions
have not varied during the experimental period, why those ZDF rats develop hyperglycemia
and diabetes earlier is something worth to be investigated. Additional experiments are needed
to confirm this observation. One possibility might be epigenetic modifications that might
happen along with the aging of the breeding pairs. Epigenetic changes might have altered the
metabolism in ZDF rats without changing the genetic coding sequence (238). There is
increasing evidence that epigenetic mechanisms are related to T2DM, and these mechanisms
may be studied in the future to explain possible differences here (238, 239).
Due to mutations in the leptin receptor, male ZDF rats have hyperphagia after weaning
and develop diabetes at 8 to 10 weeks of age (240). In studies involving animals of a single
age, the presence of hyperglycemia at that age does not necessarily reflect the length of time
that hyperglycemia exists, which may be very important. Because our current study was
terminated when the rats are 11 weeks old, it is not known whether ZDF rats will develop more
severe insulin resistance at a later age and affected by VA status. The age at which β cell failure
occurs is likely to be variable (240). Therefore, in future studies, we should extend the treatment
time to see whether the blood sugar levels of those ZDF will rise even more, which allows us
to see more dramatic differences among rats with different VA statuses.
2.2 GLUT4 studies
RA and/or insulin treatments affects the expression of GLUT4 in rat L6 skeletal muscle
cells. It indicates that muscle glucose metabolism can be affected by VA signaling system.
140

When L6 cells were fractionated to prepare different lysates for analysis of GLUT4 expression,
the effect of RA and/or insulin were different in different fractions. This demonstrates that
method and buffers of cell lysis should be chosen carefully for the analysis of GLUT4 protein
in L6 skeletal muscle cells or muscle tissues in the future. An efficient method and a buffer
need to be determined when we study GLUT4 levels.
The recombinant adenovirus (Ad-mGLUT4) constructed in this dissertation allows
overexpression of GLUT4 in cells. Ad-mGLUT4 is not only a useful tool to confirm GLUT4
expression, but also a tool that can be used to study GLUT4-mediated glucose transport in cells.
In order to determine whether Ad-mGLUT4 can be used in L6 cells before, during and after
differentiation, we investigated whether Ad-mGLUT4 can infect L6 cells before or after
differentiation, and affect the differentiation of L6 cells. We have done the following
preliminary studies. (1) Ad-mGLUT4 and β-gal (a transfection control virus) were added to L6
cells, and then cells were allowed to differentiate for 2, 4 and 6 days before being lysed. L6
cells were directly lysed in 400 ul of 1 x SDS loading buffer to obtain the total cell lysate. The
GLUT4 expression levels in L6 cells uninfected, and Ad-mGLUT4 or β-gal infected were
determined using EMD’s anti-GLUT4 antibody in Western blot. As shown in Figure 4-1A, L6
can still successfully differentiate after being infected by Ad-mGLUT4. The expression level
of GLUT4 transfected with Ad-mGLUT4 increases with L6 differentiation. (2) Ad-mGLUT4
or β-gal was added to L6 cells after the differentiation process started for 2, 4 and 6 days. Two
days after the transfection, cells were directly lysed in 400 ul of 1 x SDS loading buffer to
obtain the total cell lysate for Western blot analysis. The GLUT4 expression levels in L6 cells
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uninfected, infected with Ad-mGLUT4 or β-gal were determined using EMD’s anti-GLUT4
antibody in Western blot. L6 cells appeared to cease to differentiate after infected with AdmGLUT4. There is a decrease of GLUT4 overexpression when L6 cells infected by AdmGLUT4 after differentiated for 6 days and compare to that of L6 cells differentiated for 2 and
4 days (Figure 4-1B). In the future, these phenomena need to be investigated further to confirm
the effects of GLUT4 overexpression on the L6 cells differentiation.
3. Summary
The work described in this dissertation helps us to understand the effect of VA status on
the development of T2DM and the effect of VA signaling on the expression level of GLLUT4
in skeletal muscle. Reduction of VA status appears to ameliorate the obesity and T2DM
development in ZDF rats. This phenomenon clearly shows that VA contributes to the T2DM
development. Therefore, VA intake should be closely monitored for people with obesity and
diabetes.
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Figure 4-1: GLUT4 expression level in Ad-mGLUT4 infected L6 cell before or after differentiation. (A)
Ad-mGLUT4 (as (1) and (2)) and β-gal were added to infect L6 cells when L6 cells differentiate on day 2, 4 and
6. (B) Ad-mGLUT4 (as (1) and (2)) and β-gal added after the differentiation process of L6 cells started for 2, 4
and 6 days.
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